Biocompatible controlled release coatings for medical devices and related methods

ABSTRACT

Biocompatible coatings for medical devices are disclosed. Specifically, polymer coatings designed to control the release of bioactive agents from medical devices in vivo are disclosed wherein the solubility parameters of polymers and drugs are closely matched to control elute rate profiles. The present application also discloses providing vascular stents with controlled release coatings and related methods for making these coatings.

RELATED APPLICATION

This application is a continuation-in-part of Patent Cooperation Treatypatent application number PCT/US04/26516 filed Aug. 12, 2004 whichclaims priority to U.S. Provisional Patent Application Ser. No.60/495,143 filed Aug. 13, 2003, now abandoned, which is acontinuation-in-part of U.S. patent application Ser. No. 10/393,880filed Mar. 20, 2003.

FIELD OF THE INVENTION

This invention relates generally to biocompatible coatings for medicaldevices. More specifically, the present invention relates to polymercoatings designed to control the release of bioactive agents from amedical device. Even more specifically the present invention relates toproviding vascular stents with controlled release coatings and relatedmethods for making these coatings.

BACKGROUND OF THE INVENTION

Medical devices are used for myriad purposes on and throughout ananimal's body. They can be simple ex vivo devices such as adhesivebandages, canes, walkers and contact lenses or complex implantabledevices including pace makers, heart valves, vascular stents, cathetersand vascular grafts. Implantable medical devices must be biocompatibleto prevent inducing life threatening adverse physiological responsesbetween the implant recipient and device.

Recently, highly biocompatible polymers have been formulated to provideimplantable medical devices with coatings. These coatings not onlyincrease an implant's tissue compatibility but can also function asbioactive agent reservoirs. However, designing polymer coatings formedical devices have proven problematic. All medical device coatingsmust be non-toxic, durable and adhere well to device surfaces.Additionally, when the medical device comes into intimate contact withunprotected tissues such as blood and internal organs it must also bebiocompatible. Furthermore, if the medical device is designed to bepliable either in operation or deployment, the coating must resistcracking, fracture and delamination.

Moreover, medical devices intended to act as bioactive agent (drug)reservoirs must not only be biocompatible, structurally stable andresistant to delamination, but also chemically compatible with the drugto be deployed. Furthermore, if the reservoir is also intended tocontrol the drug's release rate into adjacent tissue the polymer usedmust possess other highly specialized properties as well.

Presently, designing a biocompatible polymer coating having the desiredphysical and chemical properties has been largely a process of trial anderror. Material scientists skilled in polymer chemistry make apreliminary polymer selection based largely on educated guesses. Next aseries of experiments designed to establish the new coatingcomposition's performance characteristics are performed and the resultscompared to an idealized model. However, very few potential polymercompositions will possess all of the desired properties required for amedical device controlled release coating. Consequently, presentcontrolled release coating development processes are tedious, timeconsuming and seldom result in an optimized medical device coatinghaving the combination of biocompatibility, ductility, surfaceadhesiveness and drug-polymer solubility.

Drug-polymer physical chemistry and the physical characteristics of thecoating itself, such as coating thickness, are the two most importantfactors in determining a polymer matrix's drug elusion profile. Highlycompatible drug-polymer combinations usually result in more even elutionrates and are therefore preferable for most in vivo applications.Polymer-drug compatibility is a function of drug-polymer miscibility.The degree of miscibility, or compatibility, between a drug and apolymer carrier can be ascertained by comparing their relativesolubility parameters. However, as will be more fully developed below,balancing drug elution rates with biocompatibility, ductility andadhesiveness requires more than merely matching a single polymer with adrug based on their total solubility parameters alone.

Therefore, it is an object of the present invention to provide medicaldevice controlled release coatings made using a process that reducestrial and error and results in drug delivery systems having idealphysical and chemical properties.

Specifically, it is an object of the present invention to providemedical device coating systems that are flexible, do not delaminate fromthe device's surface, are highly biocompatible and provide for thecontrolled release of bioactive agents.

SUMMARY OF THE INVENTION

The present invention generally provides methods and related polymercompositions useful for controlling drug release in vivo. Specifically,these methods and related polymer compostions are useful in providingcontrolled release coatings for medical devices. In one embodiment themedical device is subjected to compressive, expansive or flexion forcesduring use and/or deployment.

The controlled release polymer coatings of the present invention areintended for use inside an animal's body where the device will remain inintimate contact with body tissues for a prolonged time period.Therefore, in one embodiment of the present invention, the coatingcompostions of the present invention must be biocompatible,non-thrombogenic, non-inflammatory, lubricious and non-bioerodable.

In another embodiment of the present invention the controlled releasepolymer coatings must be ductile and possess glass transition points(Tg) sufficient to maintain elasticity/ductility at and near bodytemperature. In another embodiment of the present invention thecontrolled release polymer coatings have a Tg wherebyelasticity/ductility is maintained from approximately −20° C. to 50° C.and above.

In one embodiment of the present invention the controlled releasepolymer coatings are compatible polymer blends or terpolymers. The novelcompatible polymer blends and terpolymers made in accordance with theteachings of the present invention provide biocompatible,non-thrombogenic, non-bioerodable, elasticity/ductile coatings forimplantable medical devices. These novel medical device coatings alsoprovide for localized, controlled release drug delivery.

The novel compatible polymeric controlled release coatings of thepresent invention are prepared using novel methods of carefully matchingspecific polymer Tg and solubility parameters with drug solubility. Inone embodiment of the present invention Hansen solubility parameters(dispersion force [δ_(D)], polar force [δ_(P)], and hydrogen bondingforce [δ_(H)]) are used to design polymer compositions having a totalsolubility parameter (δ_(T)) within a defined range for the selecteddrug, or drug combination and a Tg appropriate for the compatiblepolymeric controlled release coating's intended use.

In one embodiment of the present invention the compatible polymericcontrolled release coatings of the present invention are a blend ofterpolymers, copolymers and homopolymers.

In another embodiment of the present invention the drug or drugcombination has a δ_(T) approximately equal to the polymer composition'sδ_(T).

In another embodiment methods are provided for selecting individualpolymers having Hansen solubility parameters optimized to achievepredetermined polymer composition performance characteristics includingbiocompatibility, elasticity/ductility, erosion resistance, and drugrelease profile thus forming the compatible controlled release coatingsof the present invention.

Another embodiment of the present invention includes methods for usingHansen solubility parameters to provide a compatible polymericcontrolled release coatings for a medical device wherein the coatingcomprises a terpolymer having a drug elusion profile and Tg suitable forlong term deployment in a hemodynamic environment.

In one embodiment of the present invention the polymer compositions haveδ_(T) values in the range of approximately 15 to 25δ (J^(1/2)/cm^(3/2)).

It is an objective of the present invention to provide methods formaking compatible polymeric controlled release coatings having targetdiffusivities as well as the compatible polymeric controlled releasecoatings themselves. The target diffusivities being tunable usingcopolymers and terpolymers having solubility parameters closely matchedto the solubility parameter of the bioactive agent. One method forachieving a target diffusivity in accordance with the teachings of thepresent invention is to blend homopolymers and/or copolymers such that aδ_(T) is within approximately 10 J^(1/2)/cm^(3/2) of the bioactiveagent.

For example, in one embodiment of the present invention at least twopolymers are selected having Hansen solubility parameters and Tg valuesbalanced such that the resulting polymer composition is compatible withthe bioactive agent. In this embodiment particular attention is given tocompensating for undesirable polymer physical qualities present inotherwise desirable polymers. The physical factors to be compensated toinclude Hansen solubility parameters selected from the group consistingof δ_(D), δ_(P) and δ_(H). The resulting compatible polymer blendpossesses net physical-chemical properties ideal for the bioactive agentto be released and the release kinetics desired. As used herein thisprocess, and others described below are collectively referred to as“tuning” the polymer composition and the resulting compatible polymericcontrolled release coatings are referred to herein as “tunable.”

Additional tunable compatible polymeric controlled release coatings madein accordance with the teachings of the present invention include, butare not limited to hydrophobic or hydrophilic bioactive agents and acompatible polymer blend comprising at least two polymers, each with atleast one solubility parameter, wherein: the difference between thesolubility parameter of the bioactive agent and at least one solubilityparameter of at least one of the polymers is no greater than about 10J^(1/2)/cm^(3/2), and/or the difference between at least one solubilityparameter of each of at least two polymers is no greater than about 5J^(1/2)/cm^(3/2); at least one polymer has an bioactive agentdiffusivity higher than the target diffusivity and at least one polymerhas an bioactive agent diffusivity lower than the target diffusivity;the molar average solubility parameter of the blend is no greater than25 J^(1/2)/cm^(3/2); and the swellability of the blend is no greaterthan 10% by volume.

Another embodiment of the present invention includes a method for makingtunable compatible polymeric controlled release coatings. The methodcomprises providing a bioactive agent having a molecular weight nogreater than about 1200 g/mol; selecting at least two polymers, wherein:the difference between the solubility parameter of the bioactive agentand at least one solubility parameter of each of the polymers is nogreater than about 10 J^(1/2)/cm^(3/2), and/or the difference between atleast one solubility parameter of each of the at least two polymers isno greater than about 5 J^(1/2)/cm^(3/2); and the difference between atleast one Tg of each of the at least two polymers is sufficient toinclude the target diffusivity; combining the at least two polymers toform a compatible polymer blend; and combining the compatible polymerblend with the bioactive agent to form an bioactive agent deliverysystem having the preselected dissolution time through a preselectedcritical dimension of the compatible polymer blend.

A further method for making tunable compatible polymeric controlledrelease coatings in accordance with the present invention includeproviding a bioactive agent having a molecular weight greater than about1200 g/mol; selecting at least two polymers, wherein: the differencebetween the solubility parameter of the bioactive agent and at least onesolubility parameter of each of the polymers is no greater than about 10J^(1/2)/cm^(3/2), and/or the difference between at least one solubilityparameter of each of the at least two polymers is no greater than about5 J^(1/2)/cm^(3/2); and the difference between the swellabilities of theat least two polymers is sufficient to include the target diffusivity;combining the at least two polymers to form a compatible polymer blend;and combining the compatible polymer blend with the bioactive agent toform an bioactive agent delivery system having the preselecteddissolution time through a preselected critical dimension of thecompatible polymer blend.

The compatible polymeric controlled release coatings of the presentinvention are used to coat drug eluting medical devices. In oneembodiment of the present invention the medical device is selected fromthe non-limiting group consisting of vascular stents, vascular stentgrafts, urethral stents, bile duct stents, catheters, inflationcatheters, injection catheters, guide wires, pace maker leads,ventricular assist devices, and prosthetic heart valves.

In another embodiment the drug, or drug combination eluted from thecompatible controlled release coatings of the present invention include,but are not limited to bioactive agents such as anti-proliferativecompounds, cytostatic compounds, cytotoxic compounds, anti-inflammatorycompounds, analgesics, antibiotics, protease inhibitors, tyrosine kinaseinhibitors, aldosterone inhibitors, bisphosphonates, statins, nucleicacids, polypeptides, proteins and gene delivery vectors includingrecombinant micro-organisms, liposomes, and the like.

In another embodiment of the present invention the coated medical deviceis intended to treat physiological and anatomical pathologies in ahemodynamic region of an animal such as the cardiovascular system, therespiratory system, the neurological system and the peripheral vascularsystem. In one embodiment of the present invention the medical device isa vascular stent used to treat, inhibit, palliate or prevent vascularocclusions and vulnerable plaque. In another embodiment of the presentinvention the medical device is a vascular graft used to treat, inhibit,palliate or prevent aneurysms.

In one particular non-limiting example the present invention includes avascular stent having a compatible controlled release coating made inaccordance with the present invention. The vascular stent is used totreat an existing vascular occlusion in at least one coronary artery. Aterpolymer-based coating mediates the controlled release of a bioactivecompound that inhibits restenosis or stabilized vulnerable plaque. Whenthe stent is used to inhibit restenosis, the bioactive compound is ananti-proliferative including, but not limited to, macrolide antibioticsincluding FKBP 12 binding compounds, anti-inflammatory compounds,estrogens, chaperone inhibitors, protein-tyrosine kinase inhibitors,peroxisome proliferator-activated receptor gamma ligands (PPARγ),hypothemycin, nitric oxide, anti-sense nucleotides and transformingnucleic acids. Stents for stabilizing vulnerable plaque may deploy anyof the aforementioned bioactive compounds alone or in combination withanti-inflammatory compounds and/or protease inhibitors, specificallymatrix metalloproteinase inhibitors (MMPIs) such as tetracycline-classantibiotics.

The compatible polymeric controlled release coatings made in accordancewith the teachings of the present invention can be made form anycombination of polymers that combine to form novel polymer compositionsthat exhibit the combined properties of biocompatibility, highelasticity/ductility, resistance to erosion, elasticity, and controlleddrug release. Suitable non-limiting exemplary monomers include hydroxyalkyl methacrylate, N-vinyl pyrrolidinone, alkyl methacrylate, vinylalcohols, acrylic acids, acrylamides, ethylene, vinyl acetate, ethyleneglycol di(meth)acrylate, methacrylic acid and terpolymers, co-polymersand homopolymers thereof.

The present invention also provides a specific terpolymer-baseddrug-eluting coating for a vascular device comprising a terpolymer, aco-polymer and a homopolymer blended with a tetrazole-containingmacrolide immunomodulator (referred to herein as ABT-578). In thisembodiment of the present invention the polymer-drug coating (referredto herein as Matrix™) has been specifically engineered to releaseABT-578 at a controlled rate as depicted in FIG. 7. The polymerconstituents of Matrix™ include a terpolymer (C19) comprising themonomer subunits vinyl acetate (VAc), an alkyl methacrylates (AMA),specifically hexylmethacrylate, and N-vinylpyrrolidone (NVP) wherein therelative concentrations of each range between approximately 1-10% (VAc),65-80% (AMA) and 10-20% (NVP), a copolymer (C10) comprising the monomersubunits vinyl acetate (VAc), an alkyl methacrylates (AMA), specificallyn-butyl methacrylate wherein the relative concentrations of each rangebetween approximately 1-10% (VAc) and 85-99% (AMA) and a homopolymer(PVP) comprising polyvinyl pyrrolidone. In a preferred embodimentMatrix™ comprises 65 weight percent polymer blend and 35 weight percentdrug wherein the polymer blend comprises comprising 20-30% C10, 60-70%C19 and 5-15% PVP and the drug is ABT-578.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 graphically depicts idealized first-order kinetics associatedwith drug release from a polymer coating.

FIG. 2 graphically depicts idealized zero-order kinetics associated withdrug release from a polymer coating.

FIG. 3 depicts a tortuous path tubing system used to test coatingdurability.

FIG. 4 depicts a medical device, specifically a vascular stent havingthe coating made in accordance with the teachings of the presentinvention thereon.

FIG. 5 a-d depict cross sections of the various coating configurationsused to provide vascular stents with the controlled release coatingsmade in accordance with the teachings of the present invention.

FIG. 6 depicts a vascular stent having a coating made in accordance withthe teachings of the present invention mounted on a suitable deliverydevice—a balloon catheter.

FIG. 7 depicts the drug elution profile a terpolymer-based coating ofthe present invention compared with homopolymer-based andco-polymer-based coatings made using monomeric subunits of theterpolymer based coating.

DEFINITION OF TERMS

Prior to setting forth the invention, it may be helpful to anunderstanding thereof to set forth definitions of certain terms thatwill be used hereinafter:

Abbreviations: Certain non-standard abbreviations are used herein forconvenience. Each abbreviation has been clearly defined throughout thespecification. However, in order to be certain that the reader clearlyunderstands the abbreviations used herein they are offered again here.ABT-578 refers to the tetrazole-containing macrolide immunomodulatordepicted in Formula 1 below. Matrix™ is a proprietary trade name ofMedtronic Vascular, Inc. Santa Rosa, Calif. and comprises a controlledrelease polymer coating including a terpolymer (C19), a co-polymer (C10)and a homopolymer (PVP) and an anti-restenotic concentration of a drug(see Tables 1 and 2 below for details). Wherein C19 comprises themonomer subunits hexylmethacrylate, N-vinylpyrrolidone and vinylacetate, C10 comprises the monomer subunits butylmethacrylate and vinylacetate and PVP comprises polyvinylpyrrolidone. In a preferredembodiment Matix™ comprises 27% C10, 63% C19 and 10% PVP. When used asdrug-releasing coating in accordance with the teachings of the presentinvention Matix™ comprises 65 weight percent polymer blend and 35 weightpercent drug wherein the drug is ABT-578.

Animal: As used herein “animal” shall include mammals, fish, reptilesand birds. Mammals include, but are not limited to, primates, includinghumans, dogs, cats, goats, sheep, rabbits, pigs, horses and cows.

Biocompatible: As used herein “biocompatible” shall mean any materialthat does not cause injury or death to the animal or induce an adversereaction in an animal when placed in intimate contact with the animal'stissues. Adverse reactions include inflammation, infection, fibrotictissue formation, cell death, or thrombosis.

Bioactive agent: As used herein “bioactive agent” shall includedanti-proliferative compounds, cytostatic compounds, toxic compounds,anti-inflammatory compounds, analgesics, antibiotics, proteaseinhibitors, statins, nucleic acids, polypeptides, and delivery vectorsincluding recombinant micro-organisms, liposomes, the like (see Drugsbelow).

Controlled release: As used herein “controlled release” refers to therelease of a bioactive compound from a medical device surface at apredetermined rate. Controlled release implies that the bioactivecompound does not come off the medical device surface sporadically in anunpredictable fashion and does not “burst” off of the device uponcontact with a biological environment (also referred to herein a firstorder kinetics) unless specifically intended to do so. However, the term“controlled release” as used herein does not preclude a “burstphenomenon” associated with deployment. In some embodiments of thepresent invention an initial burst of drug may be desirable followed bya more gradual release thereafter; an initial gradual release followedby a subsequent burst. The release rate may be steady state (commonlyreferred to as “timed release” or zero order kinetics), that is the drugis released in even amounts over a predetermined time (with or withoutan initial burst phase) or may be a gradient release. A gradient releaseimplies that the concentration of drug released from the device surfacechanges over time.

Compatible: As used herein “compatible” refers to a composition possessthe optimum, or near optimum combination of physical, chemical,biological and drug release kinetic properties suitable for a controlledrelease coating made in accordance with the teachings of the presentinvention. Physical characteristics include durability andelasticity/ductility, chemical characteristics include solubility and/ormiscibility and biological characteristics include biocompatibility. Thedrug release kinetic should be either near zero-order or a combinationof first and zero-order kinetics.

Drug(s): As used herein “drug” shall include any bioactive agent havinga therapeutic effect in an animal. Exemplary, non limiting examplesinclude anti-proliferatives including, but not limited to, macrolideantibiotics including FKBP 12 binding compounds, estrogens, chaperoneinhibitors, protease inhibitors, protein-tyrosine kinase inhibitors,peroxisome proliferator-activated receptor gamma ligands (PPARγ),hypothemycin, nitric oxide, bisphosphonates, epidermal growth factorinhibitors, antibodies, proteasome inhibitors, antibiotics, anti-sensenucleotides and transforming nucleic acids.

Ductility: As used herein “ductility, or ductile” is a polymer attributecharacterized by the polymer's resistance to fracture or cracking whenfolded, stressed or strained at operating temperatures. When used inreference to the polymer coating compostions of the present inventionthe normal operating temperature for the coating will be between roomtemperature and body temperature or approximately between 15° C. and 40°C. Polymer durability in a defined environment is often a function ofits elasticity/ductility.

Glass Transition Point: As used herein “glass transition point” or “Tg”is the temperature at which an amorphous polymer becomes hard andbrittle like glass. At temperatures above its Tg a polymer is elastic orrubbery; at temperatures below its Tg the polymer is hard and brittlelike glass. Tg may be used as a predictive value forelasticity/ductility.

Homopolymer: As used herein “homopolymer” shall mean a polymer beingcomposed of a single monomer.

Hydrophillic: As used herein in reference to the bioactive agent, theterm “hydrophilic” refers to a bioactive agent that has a solubility inwater of more than 200 micrograms per milliliter.

Hydrophobic: As used herein in reference to the bioactive agent the term“hydrophobic” refers to a bioactive agent that has a solubility in waterof no more than 200 micrograms per milliliter.

Polymer subunits: As used herein “polymer subunit” or “subunit” refersto the polymer's individual molecular building blocks. In homopolymersthe subunits are identical monomers such as polyethylene or polystyrene.However, copolymers can have numerous possible configurations.Co-polymers are the simplest copolymer and will be used in the followingexample. Co-polymers are composed of two dissimilar subunits. Thesubunits can be separate monomers, or oligomers. For example, aco-polymer having monomeric subunits is composed of two monomers such asethylene (E) and styrene (S). The polymer chain can be random (forexample, DNA and polypeptides are quintessential random polymers),non-random, blocked or segmented. In random co-polymers, as the nameimplies, there is no defined order to the monomer sequence, for example--EESESSEESSES-- (of course reaction kinetics may favor one couplingreaction over another; these examples are merely for illustrativepurposes). Non-random co-polymers would have an alternatingconfiguration such as ---ESESESESESESESES--. Block copolymers have ahigh number of covalently bonded repeat subunits such as-EEEEEEEESSSSSSSSSEEEEEEEEE—(ABA configuration) or-EEEEEEEEEEESSSSSSSSSSS—(an ABn configuration). Finally, segmentedco-polymers have a small number of repeat subunits such as--EESSEESSEESS-. If a third polymer is added, a terpolymer results. Forexample, say acrylic acid is added (A). A random terpolymer would looklike --AAESASSEAEESAAESEASEASEA--. A non-random terpolymer would looklike --ASEASEASEASEASEASEASE--. And a block terpolymer may look likethis --AAASSSEEEAAASSSEEEAAASSSEEE--. There are myriad other possibleconfigurations depending on the number of monomeric subunits involved.Still more complex copolymers are possible when the subunits arepolymers themselves (oligomeric subunits). Copolymer and terpolymerscomposed of oligomeric subunits often resemble random and block polymersin their behavior and therefore will not be considered further. Finally,this brief description of polymer primary structure (the chain makeup)did not consider graft polymers (where monomer and polymer side chainsare attached as pendent groups to the primary polymer chain) orcrosslinking between chains and/or pendent groups (secondary polymerstructure). However, any and all of the primary and secondary structuresdiscussed herein and variations thereon are considered within the scopeof the present invention.

Units of Measure: As used herein solubility parameters for polymers andsolvents will be expressed in δ as originally defined by Hildebrand andHansen (see for example Properties of Polymers. 1990. 3^(rd) edition. D.W. van Krevelen. Elsevier press. ISBN 0-444-88160-3. The entire contentsor which are herein incorporated by reference). δ is a thermodynamicunit expressed in J^(1/2)/cm^(3/2). However, the reader is cautionedthat beginning in 1984 a new value for δ has been adopted and designatedδ(SI) and expressed in MPa^(1/2). To convert between δ(J^(1/2)/cm^(3/2)) and δ(SI) (MPa^(1/2)) multiply δ by 2.0045 or divideδ(SI) by 0.488.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed at engineering polymers that provideoptimized drug-eluting medical devices coatings. Specifically, polymersmade in accordance with teachings of the present invention providedurable biocompatible coatings for medical devices intended for use inhemodynamic environments. In one embodiment of the present inventionvascular stents are coated using the polymer compositions of the presentinvention. Vascular stents are chosen for exemplary purposes only. Thoseskilled in the art of material science and medical devices will realizethat the polymer compositions of the present invention are useful incoating a large range of medical devices. Therefore, the use of thevascular stent as an exemplary embodiment is not intended as alimitation.

Vascular stents present a particularly unique challenge for the medicaldevice coating scientist. Vascular stents (hereinafter referred to as“stents”) must be flexible, expandable, biocompatible and physicallystable. Stents are used to relieve the symptoms associated with coronaryartery disease caused by occlusion in one or more coronary artery.Occluded coronary arteries result in diminished blood flow to heartmuscles causing ischemia induced angina and in severe cases myocardialinfarcts and death. Stents are generally deployed using catheters havingthe stent attached to an inflatable balloon at the catheter's distalend. The catheter is inserted into an artery and guided to thedeployment site. In many cases the catheter is inserted into the femoralartery or of the leg or carotid artery and the stent is deployed deepwithin the coronary vasculature at an occlusion site.

Vulnerable plaque stabilization is another application for coateddrug-eluting vascular stents. Vulnerable plaque is composed of a thinfibrous cap covering a liquid-like core composed of an atheromatousgruel. The exact composition of mature atherosclerotic plaques variesconsiderably and the factors that effect an atherosclerotic plaque'smake-up are poorly understood. However, the fibrous cap associated withmany atherosclerotic plaques is formed from a connective tissue matrixof smooth muscle cells, types I and III collagen and a single layer ofendothelial cells. The atheromatous gruel is composed of blood-bornelipoproteins trapped in the sub-endothelial extracellular space and thebreakdown of tissue macrophages filled with low density lipids (LDL)scavenged from the circulating blood. (G. Pasterkamp and E. Falk. 2000.Atherosclerotic Plaque Rupture: An Overview. J. Clin. Basic Cardiol.3:81-86). The ratio of fibrous cap material to atheromatous grueldetermines plaque stability and type. When atherosclerotic plaque isprone to rupture due to instability it is referred to a “vulnerable”plaque. Upon rupture the atheromatous gruel is released into the bloodstream and induces a massive thrombogenic response leading to suddencoronary death. Recently, it has been postulated that vulnerable plaquecan be stabilized by stenting the plaque. Moreover, vascular stentshaving a drug-releasing coating composed of matrix metalloproteinaseinhibitor dispersed in, or coated with (or both) a polymer may furtherstabilize the plaque and eventually lead to complete healing.

As used herein after “treatment site” shall mean a vascular occlusion, avulnerable plaque region or an aneurysm.

Once positioned at the treatment site the stent or graft is deployed.Generally, stents are deployed using balloon catheters. The balloonexpands the stent gently compressing it against the arterial lumenclearing the vascular occlusion or stabilizing the plaque. The catheteris then removed and the stent remains in place permanently. Mostpatients return to a normal life following a suitable recovery periodand have no reoccurrence of coronary artery disease associated with thestented occlusion. However, in some cases the arterial wall's initma isdamaged either by the disease process itself or as the result of stentdeployment. This injury initiates a complex biological responseculminating is vascular smooth muscle cell hyperproliferation andocclusion, or restenosis at the stent site.

Recently significant efforts have been devoted to preventing restenosis.Several techniques including brachytherapy, excimer laser, andpharmacological techniques have been developed. The least invasive andmost promising treatment modality is the pharmacological approach. Apreferred pharmacological approach involves the site specific deliveryof cytostatic or cytotoxic drugs directly to the stent deployment area.Site specific delivery is preferred over systemic delivery for severalreasons. First, many cytostatic and cytotoxic drugs are highly toxic andcannot be administered systemically at concentrations needed to preventrestenosis. Moreover, the systemic administration of drugs can haveunintended side effects at body locations remote from the treatmentsite. Additionally, many drugs are either not sufficiently soluble, ortoo quickly cleared from the blood stream to effectively preventrestenosis. Therefore, administration of anti-restenotic compoundsdirectly to the treatment area is preferred.

Several techniques and corresponding devices have been developed todeploy anti-restenotic compounds including weeping balloon and injectioncatheters. Weeping balloon catheters are used to slowly apply ananti-restenotic composition under pressure through fine pores in aninflatable segment at or near the catheter's distal end. The inflatablesegment can be the same used to deploy the stent or separate segment.Injection catheters administer the anti-restenotic composition by eitheremitting a pressurized fluid jet, or by directly piercing the arterywall with one or more needle-like appendage. Recently, needle cathetershave been developed to inject drugs into an artery's adventitia.However, administration of anti-restenotic compositions using weepingand injection catheters to prevent restenosis remains experimental andlargely unsuccessful. Direct anti-restenotic composition administrationhas several disadvantages. When anti-restenotic compositions areadministered directly to the arterial lumen using a weeping catheter,the blood flow quickly flushes the anti-restenotic composition downstream and away from the treatment site. Anti-restenotic compositionsinjected into the lumen wall or adventitia may rapidly diffuse into thesurrounding tissue. Consequently, the anti-restenotic composition maynot be present at the treatment site in sufficient concentrations toprevent restenosis. As a result of these and other disadvantagesassociated with catheter-based local drug delivery, investigatorscontinue to seek improved methods for the localized delivery ofanti-restenotic compositions.

The most successful method for localized anti-restenotic compositiondelivery developed to date is the drug-eluting stent. Many drug-elutingstent embodiments have been developed and tested. However, significantadvances are still necessary in order to provide safe and highlyeffective drug delivery stents. One of the major challenges associatedwith stent-based anti-restenotic composition delivery is controlling thedrug delivery rate. Generally speaking drug delivery rates have twoprimary kinetic profiles. Drugs that reach the blood stream or tissueimmediately after administration follow first-order kinetics. FIG. 1graphically depicts idealized first-order kinetics. First-order drugrelease kinetics provide an immediate surge in blood or local tissuedrug levels (peak levels) followed by a gradual decline (trough levels).In most cases therapeutic levels are only maintained for a few hours.Drugs released slowly over a sustained time where blood or tissueconcentrations remains steady follow zero-order kinetics. FIG. 2graphically depicts idealized zero-order kinetics. Depending on themethod of drug delivery and tissue/blood clearance rates, zero-orderkinetics result in sustained therapeutic levels for prolonged periods.Drug-release profiles can be modified to meet specific applications.Generally, most controlled release compositions are designed to providenear zero-order kinetics. However, there may be applications where aninitial burst, or loading dose, of drug is desired (first-orderkinetics) followed by a more gradual sustained drug release (nearzero-order kinetics). The present invention provides methods fordesigning polymeric compositions having drug-release profiles thatfollow first-order kinetics, zero-order kinetics and first andzero-order kinetic combinations. Thus, among other qualities, thepresent invention provides polymeric controlled release coatingsoptimized for any application, specifically coatings for vascularimplants.

Controlling the drug-release rate from medical device surfaces ischallenging. This challenge is even greater when the device is avascular stent. Stents are deployed in a physiological and anatomicalenvironment that exposes the device and its coatings to the physicalforces associated with blood circulation. Blood circulates throughoutthe body in a closed system of arteries and veins collectively referredto as blood vessels. The physical forces associated with bloodcirculation are referred to as hemodynamic forces and include themechanical and hydrodynamic forces. For example, blood flow in andaround vessel obstructions, including medical implants can result inturbulent blood flow. Turbulent blood flow can cause shear forces whichhave an eroding effect on exposed surfaces. Furthermore, there aremechanical forces associated with blood circulation such as theexpansion and contraction of blood vessels and adjacent muscles andorgans. These mechanical forces may cause vascular implants to bend,twist and strain and may also induce friction at the interface betweenthe blood vessel lumen wall and vascular implant's surface. Finally,significant strain is placed on the stent body and coating duringdeployment. Stents are generally compressed on the distal end of thecatheter and then expanded at the deployment site. The combination ofpre-deployment compression and deployment expansion causes significantmechanical stress to the stent and any associated coating.

The present invention is directed at optimized drug releasing medicaldevice coatings suitable for use in hemodynamic environments. Thecoatings of the present invention are composed of polymers having atleast one bioactive agent dispersed therein. The polymeric compositionsof the present invention have been specifically formulated to providemedical device coatings that tenaciously adhere to medical devicesurfaces (do not delaminate), flex without fracturing (ductile), resisterosion (durable), are biocompatible and release a wide variety of drugsat controlled rates.

Polymers have been used as medical device coatings for decades toenhanced biocompatibility and erosion resistance. Moreover, in certainapplications polymer coatings may also provide electrical insulation. Itis also well known in the art that polymers can act as reservoirs and/ordiffusion barriers to control biological agent elution rates. Numerousexamples were discussed in the preceding “Background of the Invention”section.

Recently, coatings have been applied to implantable medical devices suchvascular stents, vascular stent grafts, urethral stents, bile ductstents, catheters, inflation catheters, injection catheters, guidewires, pace maker leads, ventricular assist devices, and prostheticheart valves. Devices such as these are generally subjected to flexionstrain and stress during implantation, application or both. Providingflexible medical devices such as stents with stable biocompatiblepolymer coatings is especially difficult.

There are two basic molecular morphologies that define a polymer'stertiary solid-state structure. Polymers may be either semicrystallineor amorphous depending on the nature of the polymer subunit.Semi-crystalline polymers are ridged and brittle at any temperaturebelow their melting point and are generally not suitable for coatingflexible medical devices such as stents. In addition, drugs or bioactiveagents cannot stay in the polymer crystal region, therefore, the drugsor bioactive agents loading is limited. Amorphous polymers, on otherhand, can be either rigid or elastic/ductile depending on its glasstransition point. The glass transition point of an amorphous polymer isthe temperature above which the amorphous polymer is elastic/ductile andflexible. For stent application it is desirable that the Tg be belowbody temperature. Many polymeric compostions have glass transitionpoints substantially above body temperature and are thus in the glassyor rigid state when the device is deployed and remains so once thedevice is implanted. Polymers in the “glassy” state arenon-elastic/ductile and prone to cracking, fracturing and delaminatingwhen the stent is flexed. Polymer coatings susceptible to fracture anddelaminating are especially undesirable when used on stents. Smallpolymer particles that separate from a delaminated or fractured stentcoating may be carried by the blood flow downstream where they can lodgein capillaries and obstruct blood flow to critical regions of the heart.Therefore stents and other flexible medical devices should have polymercoatings that are elastic/ductile and adhere to the device surface well.Generally, this requires that coating polymers be amorphous and haveglass transition points below body temperature.

However, polymers having extremely low Tgs are undesirable when used tocoat devices that are subjected to continual hemodynamic forces. Asgeneral rule, the lower the Tg the more rubbery a polymer becomes. Morerubbery polymers can be tacky and less durable and are more likely tobreak down when exposed to hemodynamic induced stress and wear than lessrubbery ones. This is partially due to the fact that the more rubberypolymers have higher coefficients of friction and possess lessstructural integrity. Therefore, polymers having extremely low Tgsshould not be the dominant polymer in polymer blends or copolymercompostions when designing coating polymers intend for stents and othervascular implants. In addition, extremely low Tg (e.g., rubbery)polymers tend to release drugs or bioactive materials at undesirablyfast rates due to their high free volumes.

In addition to the aforementioned structural and drug releasing profileconsiderations, polymers used as stent coatings must also bebiocompatible. Biocompatibility encompasses numerous factors that havebeen briefly defined in the preceding “Definition of Terms” section. Theneed for a polymer to be biocompatible significantly limits the numberof available options for the material scientist. Moreover, these optionsare further limited when the polymer coating is used on a device that iscontinuously exposed to hemodynamic forces. For example, stent coatingsmust remain non-thrombogenic, non-inflammatory and structurally stablefor prolong time periods.

There are generally two large, and to some extent overlapping,categories of biocompatible polymers suitable as medical devicecoatings: bioerodable (including bioresorbable polymers) andnon-bioerodable polymers. Coating compositions of the present inventionare principally directed at the latter. However, the present invention'smethods are equally applicable to bioerodable and non-bioerodablepolymer coatings. The remaining discussion and exemplary embodimentswill be directed at non-bioerodable polymers.

Non-erodable polymers can be hydrophilic, hydrophobic or amphiphilicdepending on the polarity of the monomers used and the ratio ofhydrophobic to hydrophilic monomers. Hydrophilic polymers are polarmolecules that are miscible with polar solvents and are generallylubricious while contacting body fluids. Hydrophilic polymers are oftenused in biomedical applications to produce lubricious hydrogels.Hydrogels, include polymer compositions that can absorb more than 20%its weight in water while maintaining a distinct three-dimensionalstructure. This definition includes dry polymers that swell in aqueousenvironments in addition to the water-swollen polymer compositions.Hydrogels are divided into two general classes and “aerogels” and“xerogels.” Aerogels are porous hydrogels that absorb water into itsmacroporous structure without exhibiting significant swelling. Moreover,aerogels do not collapse and contract upon drying. Consequently,aerogels are ideally suited for applications that require high waterabsorbency with minimum change is polymer volume is desired. In contrastxerogels are nonporous gels absorb water into the polar regions of thepolymer's macro structure resulting in considerable swelling andcorresponding volume increase.

Preferably, a polymer having a relatively high swellability is combinedwith a polymer having a relatively low swellability. For example, amiscible polymer blend for an active agent having a molecular weight ofgreater than 1200 g/mol includes polyvinyl pyrollidone-vinyl acetatecopolymer, which has a swellability of greater than 100%, and poly(etherurethane), which has a swellability of 60%. By combining such high andlow swell polymers, the active agent delivery system can be tuned forthe desired dissolution time of the active agent.

Swellabilities of the miscible polymer blends are also used as a factorin determining the combinations of polymers for a particular activeagent. For delivery systems in which the active agent has a molecularweight of greater than 1200 g/mol, whether it is hydrophilic orhydrophobic, polymers are selected such that the swellability of theblend is greater than 10% by volume. The swellability of the blend isevaluated without the active agent incorporated therein.

Hydrophobic polymers such as polytetrafluoroethylene (PTFE AKA Teflon®)do not swell but can also be biocompatible. Teflon® has an extremely lowcoefficient of friction and is one of the most widely used hydrophobicbiocompatible polymers. However, PTFE's slipperiness makes it difficultto handle and manipulate. Moreover, PTFE is a stiff chemically inertpolymer and bonds poorly to surfaces. Furthermore, PTFE's extremelyhydrophobic nature significantly limits its chemical compatibility withmany bioactive agents. Recently, nanoporous PTFE has been developed thatcan be used as a barrier coating, or cap coat, that mediates bioactiveagent release from an underlying drug reservoir (Advanced SurfaceEngineering, Inc. Eldersburg, Md.). However, nanoporous PTFE coatingsare expensive and the application process is not compatible with allmedical device surfaces and drug categories. Consequently, theusefulness of PTFE as a medical device coating is limited. There aremany other biocompatible hydrophobic polymers; however, many of thesehave a high coefficient of frictions which is undesirable in ahemodynamic environment. Moreover, many hydrophilic drugs do notdisperse well in hydrophobic polymer and therefore are not suitable drugdelivery platforms for many hydrophilic bioactive agents.

Therefore, there are four specific attributes that the stent coatingpolymers made in accordance with the teachings of the present inventionshould possess. The polymer compositions of the present invention shouldbe biocompatible, durable, elastic/ductile and possess a predetermineddrug release profile. Prior to the present invention polymer coatingdesign was largely a matter of trial and error. Previously, materialscientists based their polymer coating compositions on best guesses andprevious experience. Slight modifications were made randomly and theresulting polymer compositions were tested in vitro and in vivo.Unsuccessful polymers were eliminated from further consideration and thesuccessful polymer ultimately selected from myriad potential candidates.The present invention provides methods for reproducibly balancing thefour critical parameters of biocompatibility, durability,elasticity/ductility and drug release profile when designing controlledrelease polymer coatings. Moreover, the present invention provides novelpolymer compositions made in accordance with the teachings of thepresent invention.

One of the most fundamental physical chemical properties that must beconsidered when selecting polymers for use as controlled releasecoatings is the polymer's solubility parameters. The present inventorshave developed a novel method of using solubility parameters fordesigning polymeric compositions useful as controlled release coatingsfor devices deployed in hemodynamic environments. At its most basiclevel, the present invention employs principles of polymer physicalchemistry to match polymeric compositions with drugs so that theresulting controlled release coatings have both optimum physicalattributes and drug release kinetic profiles.

As used hereinafter the compositions of the present invention will bereferred to as “controlled release coatings.” This term shall refer to apolymeric composition that has optimum physical characteristics suchincluding biocompatibility, durability, elasticity/ductility in additionto a predetermined optimum drug releasing kinetic profile.

Polymer solubility parameters as a function of a polymer's cohesiveproperties were known to be a direct expression of the polymer'sbehavior in aqueous and organic solvents as early as 1916. However, itwas not until 1949 that Hildebrand proposed the term solubilityparameter and assigned the symbol “δ” to represent a polymers behaviorin specific solvents; as previously discussed, “δ” will be expressed inJ^(1/2)/cm^(3/2). However, Hildebrand had only considered dispersiveforces between various structural units when determining solvent/polymersolubility parameters. Later, Hansen et al. established that theinteraction between polar groups and hydrogen bonding contributedsignificantly to the total cohesive energy, and thus the solubilitybehavior of many liquids and amorphous polymers. Therefore, Hansendefined a polymer's total solubility (δ_(T)) as the interaction betweenthree distinct values: dispersion force (δ_(D)), polar force (δ_(P)),and hydrogen bonding force (δ_(H)) (see van Krevelen at pages 189-226).As used herein δ_(T) will be used to refer to the final solubilityparameter of a controlled release coating made in accordance with theteachings of the present invention. As will be evident from theteachings that follow, a controlled release coating may be a terpolymer,or a blend of copolymers and/or copolymers and homopolymers.

The present inventors have used the Hansen solubility parameters tooptimize controlled release coating compositions for stents. The presentinventors have determined that the optimum drug release kinetic profileoccurs when the polymer's solubility parameter closely matches thedrug's. However, merely matching candidate drug's solubility withpolymer's δ_(T) does not always result in a functional controlledrelease coating. As discussed extensively above there are threeadditional criteria that a successful controlled release coating mustmeet. The present inventors have determined that various homopolymers,copolymer and combinations thereof, can be designed by balancing theHansen solubility parameters of the polymer subunits and/or individualpolymers in a blend.

Generally speaking for an individual homopolymer's δ equals

[δ_(D) ²+δ_(P) ²+δ_(H) ²]^(1/2). In a copolymer the combined δs, ortotal δ (δ_(T)), equals ΣXδ₁+Xδ₂+Xδ₃+Xδ₄ . . . where X equals thepercentage of each polymer subunit (T1, T2, T3 etc) in the totalpolymer. Likewise, for a polymer blend the combined δ_(T) equalsΣXδ_(T1)+Xδ_(T2)+Xδ_(T3)+Xδ_(T4) . . . where X equals the percentage ofeach individual polymer in the blend (T1, T2, T3 etc). Therefore, thepresent inventors determined that the δ_(T) can be adjusted to match theδ for any given drug.

However, the present inventors have also determined that a copolymer'sbiocompatibility, elasticity/ductility and durability can be optimizedby altering the ratio of polymeric subunits that favor one property overanother. For example, ductility and durability are roughly a function ofthe polymer's Tg. The lower the Tg, the more ductile the polymerbecomes. However, below a certain point the polymer becomes too rubberyand its durability is adversely effected. Moreover, extremely rubberypolymers possess greater first-order kinetics than near zero-orderkinetics, consequently, extremely low Tgs are to be avoided.

The present inventors have developed a system for controlled releasecoating design that is conceptually similar to how the individual Hansensolubility parameters affect a polymer's δ. For example, hydrogenbonding capacity contributes more significantly to a controlled releasecoating's biocompatibility than other factors. Therefore, polymershaving high hydrogen bonding potential such as poly(N-vinyl pyrrolidone)increase biocompatibility.

Elasticity/ductility increases as the polymer's Tg decreases. Tg in turndecreases as the polymer's free volume increases. Free volumecorresponds to the unoccupied regions accessible to segmental motions.Free volume in turn is affected by several factors includingswellability, the number and size of pendent groups present on polymersubunits and the extent and degree of cross linking. The affects of freevolume on Tg are best appreciated with reference to examples. Comparethe effects on Tg caused by adding two different alkyl ester monomers toa terpolymer. For this example assume that the terpolymer is composed of30% vinyl acetate, 40% Y-methacrylate and 30% N-vinyl pyrrolidone. If Yequals hexyl, the resulting terpolymer has a calculated Tg of 21° C. anda calculated 8 of approximately 21. However, if lauryl methacrylate issubstituted for hexyl-methacrylate the polymers' Tg to −11 but δ remainsapproximately 21.

The preceding example demonstrates the effect that pendent chain groupsize has on Tg. Note that the larger pendent group on the laurylmethacrylate monomer dramatically decreases Tg as compared tohexyl-methacrylate while having no effect on δ. However, as previouslystated, even though δ remains the same, the release kinetics of theterpolymer using lauryl methacrylate in place of hexyl-methacrylate arenot optimum. The lauryl methacrylate-containing polymer exhibited nearfirst-order kinetics when tested. Therefore, the present inventors havediscovered that the pendent group size on hydrophobic polymers such asalkyl esters can affect polymer dispersive forces (δ_(D)) and which inturn can affect release kinetics and Tg. However, Tg can also beaffected by monomer polarity (δ_(P)). In one embodiment of the presentinvention vinyl acetate is used to modulate polymer polarity. Vinylacetates have polar groups that increase the intermolecular forces anddecrease free volume. As free volume decreases, Tg increases.

In another embodiment compatible polymer blends are made using theteachings of the present invention. As used herein compatible polymerblends shall mean two or more chemically distinct polymers, includinghomopolymers, copolymers and terpolymers that form stable mixtures thatdo not separate on standing or during prolonged use and possess theother desired physical and chemicals properties discussed herein.Methods for compatibilizing two or more polymers with at least onebioactive agent are provided accordingly. A first polymer compositionknown to have certain desirable properties such as biocompatibility andelasticity/ductility is selected. However, the Tg of the first polymermay be below the desired range and thus have poor controlled releaseproperties (for example it may have a first-order kinetic profile).Moreover, the first polymer may not have a δ compatible with thebioactive agent. Consequently, a second polymer composition havingsolubility parameters and Tg that balance the first polymer's Tg and δcan be blended with the first polymer composition to create an optimumcontrolled release coating.

For example, and not intended as a limitation, polyethylene-co-vinylacetate (PEVAc) copolymers are durable, elastic/ductile and exhibit goodadhesion to metals. However, PEVAc's low Tg renders the polymer tackyand prone to first-order drug release kinetics. Therefore, it may bedesirable to create polymer blends using PEVAc as the first polymercomposition and a second polymer that is compatible with PEVAc.Moreover, the second polymer component should have a Tg that compensatesfor PEVAc's low Tg and also possess δ values that provide a δ_(T) forthe polymer blend that approximately matches the bioactive agent's δ.However, in order to assure that the polymer blend that has a δ_(T) andTg optimized for a controlled release coating the first and secondpolymer composition must be miscible. In this example, because PEAVccontains vinyl acetate the second polymer composition should possessvinyl acetate monomers to increase miscibility. This approach helpscompatibilize the second polymer composition with PEVAc and helpsprovide a compatible polymer blend having an optimized drug releasekinetic profile.

Therefore, optimized controlled release coatings require that both δvalues and Tg be considered when selecting polymer subunits. The designof a controlled release coating made in accordance with the teachings ofthe present invention begins with selecting the drug or drug-combinationto be delivered and the desired drug release kinetic profile. Next thedrug's solubility parameter is determined and the general chemical makeup of the molecule is considered, that is, is the drug polar ornon-polar? Then, starting with the basic assumption thatlike-dissolves-like, polymer units having a δ_(P) approximately equal tothe drug are selected. However, it is important to avoid selecting alkylesters having extremely large pendent groups that may drop thecontrolled release coating's Tg below that optimum for the desiredrelease kinetics. Polymer subunits are then selected having δ_(D)'s thatwill balance the adverse effects on Tg caused by polymers having anunfavorable δ_(P). Finally, polymer subunits having δ_(H)'s necessaryfor good biocompatibility are added to the list of candidate polymericsubunits.

Adjustments to the theoretical polymer blends can be made by varyingpolymer subunit concentrations in accordance with the teachings of thepresent invention until a δ_(T) approximately equal to the drug's δ isachieved. If the Tg drops below an acceptable range for the drug releasekinetics desired the δ_(P) and δ_(D) components can be adjusted, orslightly different polymeric subunits can be selected as necessary.Finally, once the desired Tg range is reached the final concentration ofδ_(H) subunits can be adjusted to assure optimum biocompatibility. Thefinal polymer, or polymer blend, will have a δ_(T) approximately equalto the drug's δ and a Tg below body temperature, but not so low as toadversely affect the drug release kinetic profile desired. In oneembodiment of the present invention δ is between approximately 15J^(1/2)/cm^(3/2) to 21 J^(1/2)/cm^(3/2) and Tg is between approximately10° C. and 35° C.

Persons having ordinary skill in the art will realize that the abovediscussion is intended as a guide and that minor variations can be madeto the order of polymer selection and target Tg and δ values withoutdeviating from the sprit of the invention. Moreover it is with the scopeof the present invention to add polymer modifiers including crosslinkingreagents and polymer grafts to control swelling and enhance over alldurability and drug release kinetics.

However, release rate is not entirely a function of drug-polymercompatibility. Coating configurations, polymer swellability and coatingthickness also play roles. When the medical device of the presentinvention is used in the vasculature, the coating dimensions aregenerally measured in micrometers (μm). Coatings consistent with theteaching of the present invention may be a thin as 1 μm or a thick as1000 μm. There are at least two distinct coating configurations withinthe scope of the present invention. In one embodiment of the presentinvention the drug-containing coating is applied directly to the devicesurface or onto a polymer primer coat such a parylene or a parylenederivative. Depending on the solubility rate and profile desired, thedrug is either entirely soluble within the polymer matrix, or evenlydispersed throughout. The drug concentration present in the polymermatrix ranges from 0.1% by weight to 80% by weight. In either event, itis most desirable to have as homogenous of a coating composition aspossible. This particular configuration is commonly referred to as adrug-polymer matrix.

In another embodiment of the present invention a drug-free polymerbarrier, or cap, coat is applied over the drug-containing coating. Thedrug-containing coating serves as a drug reservoir. Generally, theconcentration of drug present in the reservoir ranges from abort 0.1% byweight to as much as 100%. The barrier coating participates in thecontrolling drug release rates in at least three ways. In one embodimentthe barrier coat has a solubility constant different from the underlyingdrug-containing coating. In this embodiment the drugs diffusivitythrough the barrier coat is regulated as a function of the barriercoating's solubility factors. The more miscible the drug is in thebarrier coat, the quicker it will elute form the device surface and visaversa. This coating configuration is commonly referred to as a reservoircoating.

In another embodiment the barrier coat comprises a porous network wherethe coating acts as a molecular sieve. The larger the pores relative tothe size of the drug, the faster the drug will elute. Moreover,intramolecular interactions will also determine the elution rates. Theintramolecular interactions having the greatest net effect on drugelution include the relative hydrophobicity/hydrophilicity (δ_(H)) ofthe drug-polymer interaction. These factors have already been discussedabove and apply to both the drug-containing coating as well as thebarrier coating, the less intramolecular interaction between the drugand polymer barrier coat, the faster the drug will transit the porousnetwork and enter the neighboring tissues. Persons having ordinary skillin the art of material science in combination with the teachings hereinwill readily understand that many variations on the cap coat anddrug-eluting coatings can be made to tune the target diffusivity of thepresent invention.

Swellability is also an important factor. Polymer free volume increasesproportionally to increases in swellability. Therefore, drug elutionrate increases with increasing swellability. As a result, for thepurposes of the present invention the total swellability of the polymerblend used with bioactive agents having molecular weights less or thanabout 1200 g/mol and polymer blends having a δ_(T) greater than 25J^(1/2)/cm^(3/2) should not exceed 10% by volume. Moreover, the totalswellability should not exceed 10% by volume when the active agents havemolecular weights greater than about 1200 g/mol and the polymer blendhas a δ_(T) less than 25 J^(1/2)/cm^(3/2). In both cases this remainstrue regardless of whether the bioactive agent is hydrophilic orhydrophobic.

Finally, returning to coating thickness, while thickness is generally aminor factor in determining overall drug-release rates and profile, itis never-the-less an additional factor that can be used to tune thecoatings. Basically, if all other physical and chemical factors remainunchanged, the rate at which a given drug diffuses through a givencoating is directly proportional to the coating thickness. That is,increasing the coating thickness increases the elution rate and visaversa.

We now turn to another factor that contributes to the compatiblizedcontrolled release coatings of the present invention. As mentionedearlier, coating intended for medical devices deployed in a hemodynamicenvironment must possess excellent adhesive properties. That is, thecoating must be stably linked to the medical device surface. Manydifferent materials can be used to fabricate the implantable medicaldevices including stainless steel, nitinol, aluminum, chromium,titanium, ceramics, and a wide range of plastics and natural materialsincluding collagen, fibrin and plant fibers. All of these materials, andothers, may be used with the controlled release coatings made inaccordance with the teachings of the present invention.

One embodiment of the present invention is depicted in FIG. 4. In FIG. 4a vascular stent 400 having the structure 402 is made from a materialselected from the non-limiting group materials including stainlesssteel, nitinol, aluminum, chromium, titanium, ceramics, and a wide rangeof plastics and natural materials including collagen, fibrin and plantfibers. The structure 402 is provided with a coating composition made inaccordance with the teachings of the present invention. FIG. 5 a-d arecross-sections of stent 400 showing various coating configurations. InFIG. 5 a stent 400 has a first polymer coating 502 comprising a medicalgrade primer, such as but not limited to parylene or a parylenederivative; a second controlled release coating 504; and a thirdbarrier, or cap, coat 506. In FIG. 5 b stent 400 has a first polymercoating 502 comprising a medical grade primer, such as but not limitedto parylene or a parylene derivative, and a second controlled releasecoating 504. In FIG. 5 c stent 400 has a first controlled releasecoating 504 and a second barrier, or cap, coat 506. In FIG. 5 d stent400 has only a controlled release coating 504. FIG. 6 depicts a vascularstent 400 having a coating 504 made in accordance with the teachings ofthe present invention mounted on a balloon catheter 601.

There are many theories that attempt to explain, or contribute to ourunderstanding of how polymers adhere to surfaces. The most importantforces include electrostatic and hydrogen bonding. However, otherfactors including wettability, absorption and resiliency also determinehow well a polymer will adhere to different surfaces. Therefore, polymerbase coats, or primers are often used in order to create a more uniformcoating surface. In one embodiment of the present invention medicaldevices, specifically stents, are provided with polymer primer coatsthat provide inert adhesion layers for the controlled release coatingsof the present invention. For example, and not intended as a limitation,parylene C is applied to the stent surface using vapor depositiontechniques. Parylene is a hydrophobic, biocompatible, lubricious polymerthat is transparent, flexible and meets USP class VI plasticrequirements. Moreover, parylene is a gas-phase polymerized compositionthat completely forms to device surface topologies leaving a thin,pinhole-free base coat that is readily coated with other polymers.Parylene's hydrophobic nature can present challenges to coatingscientists. However, when used in accordance with the teaching of thepresent invention, controlled release polymer compositions can beoptimized to assure good long-term adhesion to the primer coat.

The controlled release coatings of the present invention can be appliedto medical device surfaces, either primed or bare, in any manner knownto those skilled in the art. Applications methods compatible with thepresent invention include, but are not limited to, spraying, dipping,brushing, vacuum-deposition, and others. Moreover, the controlledrelease coatings of the present invention may be used with a cap coat. Acap coat as used here refers to the outermost coating layer applied overanother coating. For examples, and not intended as a limitation: a metalstent has a parylene primer coat applied to its bare metal surface. Overthe primer coat a drug-releasing terpolymer coating or blend ofhomopolymer, copolymer and terpolymer coating is applied. Over theterpolymer a polymer cap coat is applied. The cap coat may optionallyserve as a diffusion barrier to further control the drug release, orprovide a separate drug. The cap coat may be merely a biocompatiblepolymer applied to the surface of the sent to protect the stent and haveno effect on elusion rates.

The following non-limiting examples illustrate some of the variousaspects of compositions and methods used to provide implantable medicaldevices with controlled release coatings. Various polymer compositionswere prepared and analyzed in accordance with the teachings of thepresent invention. The present inventors have determined that the drugrelease rates and profiles are optimum if the polymer's total solubilityparameter (δ_(T)) is approximately equal to a bioactive agent'ssolubility parameter (δ). For the purposes of the present invention thepolymer's total solubility parameter (δ_(T)) is considered approximatelyequal to a bioactive agent's solubility parameter (δ) if theirrespective δ values fall with in plus or minus 10 J^(1/2)/cm^(3/2),and/or the difference between at least one solubility parameter of eachof the at least two polymers is no greater than about 5J^(1/2)/cm^(3/2).

Furthermore, in one embodiment of the present invention the compatiblepolymer blends are made wherein the ratio of low Tg polymer to high Tgpolymer is in the range of 20:80 to 80:20. In one particular embodimentthe ratio of low Tg polymer to high Tg polymer is 50:50. In anotherembodiment the ratio of low Tg polymer to high Tg polymer is 60:40. Inanother embodiment the ratio of low Tg polymer to high Tg polymer is70:30 In another embodiment the ratio of low Tg polymer to high Tgpolymer is 80:20. It is understood that these ratios and ranges areapproximate and that the exact ratio of low Tg polymer to high Tgpolymer is determined in accordance with the present teachings.

In another embodiment a compatible polymer blend is made form threepolymers, a terpolymer, a copolymer and a homopolymer. In one suchembodiment the Terpolymer is the low Tg polymer, the copolymer has anintermediate Tg and the homopolymer is the high Tg polymer. In oneembodiment the ration of low Tg polymer to intermediate Tg polymer tohigh Tg polymer is from approximately 60:20:20 to 80:10:10. In apreferred embodiment (Matrix™) the ratio is approximately 67:23:10. Thepreferred embodiment, Matrix™, comprises a terpolymer having a Tg in therange of 15° C. to 25° C., a copolymer having a Tg in the range of 30°C. to 40° C. and a homopolymer having a Tg in the range of 170° C. to180° C. More specifically, Matrix™ comprises a terpolymer (C19)comprising the monomer subunits hexylmethacrylate, N-vinylpyrrolidoneand vinyl acetate having a Tg of 15° C. to 20° C., a copolymer (C10)comprising the monomer subunits butylmethacrylate and vinyl acetatehaving a Tg of 32° C. to 35° C. and a homopolymer (PVP) comprisingpolyvinylpyrrolidone having a Tg of 174° C.

For exemplary purposes three anti-restenotic, bioactive compositionswere used to test the controlled release kinetics of the presentinvention. The solubility parameter for each drug is 17.5 δ. The drugswere given the laboratory designators A-19 (rapamycin), A-20(everolimus) and A-24. A-24, aka ABT-578, was assigned to atetrazole-containing macrolide antibiotic depicted in below as Formula 1(see also U.S. Pat. Nos. 6,015,815, filed Sep. 24, 1998 and 6,329,386,filed Nov. 11, 1999 both of which are hereby incorporated in theirentirety). For ease of reference, the compound depicted below in Formula1 will be referred to herein, and in the claims, as ABT-578.

Table I lists polymers used in the following exemplary embodiments.These polymers were prepared using methods known to those skilled in theart of polymer chemistry and as detailed in references such as, A.Ravve. Principles of Polymer Chemistry, Second Edition. 2000. KluwerAcademic/Plenum Publishers, New York. ISBN 0-306-46368-7; H. Allcock andF. Lampe. Contemporary Polymer Chemistry. 1981. Prentice-Hall, N.J. ISBN0-13-170258-0. and A. Tonelli. Polymers from the Inside Out. 2001.Wiley-Interscience. ISBN 0-471-38138-1. All of these references areincorporated by reference herein; additional exemplary teachings arealso provided.

The following abbreviations will be used in referring to the variousexemplary polymer compositions: VAc=vinyl acetate monomer; BMA=butylmethacrylate monomer; HMA=hexyl methacrylate monomer; LMA=laurylmethacrylate monomer; NVP=N-vinyl pyrrolidone monomer andPEVc=(poly)ethylene-vinyl acetate copolymer.

TABLE 1 POLYMER COMPOSITIONS mole % of each Polymer Polymer Compositionmonomer ID δ Tg (° C.) PVP N/A PVP 174 VAc:nBMA  5/95 A (C10) 18.0 32-35VAc:nBMA 10/90 B 18.1 21.0 VAc:nBMA 70/30 C 19.1 28 VAc:nHMA:NVP7-30/40-75/19-30 D VAc:nHMA:NVP 30/40/30 D1 21.0 21.0 VAc:nHMA:NVP20/60/20 D2 17.8 12.2 VAc:nHMA:NVP 10/70/20 D3 17.9 8.6 VAc:nHMA:NVP 9/71/20 D4 17.9 8.2 VAc:nHMA:NVP  7/73/20 D5 18.0 7.5 VAc:nHMA:NVP 7/74/19 D6 18.0 7.0 VAc:nLMA:NVP 30/40/30 E 21.0 −11 VAc:nHMA:NVP 5/77/18 F (C19) 15-20

Table 2 represents the exemplary polymer blend prepared in accordancewith the teachings of the preset invention and the resulting δ_(T) valuefor each polymer blend. The blends were prepared such that the resultingδ_(T) fell between 15 and 21δ to be compatible with drugs' δ of 17.5.

TABLE 2 EXEMPLARY COMPATIBILIZED CONTROLLED RELEASE COATINGS Weightpercent Polymer Compatibilized Polymer Blend of polymers¹ Blend ID δ_(T)PEVAc:Polymer A 50/50 I 17.7 PEVAc:Polymer A 60/40 II 17.8 PEVAc:PolymerB 50/50 III 17.8 PEVAc:Polymer B 40/60 IV 17.8 PEVAc:Polymer B:Polymer C40/50/10 V 17.9 PEVAc:Polymer B:Polymer C 40/40/20 VI 18.0 PEVAc:PolymerB:Polymer C  50/41.7/8.3 VII 17.8 PEVAc:Polymer B:Polymer C 50/33.3/16.7 VIII 17.9 PEVAc:Polymer B:Polymer C  60/33.3:6.7 IX 17.8PEVAc:Polymer B:Polymer C  60/26.7/13.3 X 17.8 PEVAc:Polymer E 20/80 XI20.2 Polymer B:Polymer D1 80/20 XII 18.0 Polymer B:Polymer D1 70/30 XIII18.0 Polymer B:Polymer D1 60/40 XIV 18.0 Polymer B:Polymer D1 50/50 XV18.0 Polymer B:Polymer D1 40/60 XVI 18.0 PVP:Polymer A:Polymer F10/23/63 Matrix ™ 20.1 ¹The percent polymer component is measured on aweight-percent basis.

EXAMPLE 1A General Method of the Two-Step Synthesis of Segmented n-ButylMethacrylate and Vinyl Acetate Copolymers

One embodiment of the present invention is exhibited by a two-stepsynthesis of a copolymer with n-butyl methacrylate and vinyl acetatesegments. In the first step of the synthesis, predetermined amounts ofn-butyl methacrylate (BMA) and vinyl acetate (VAc) were mixed in apre-dried glass reactor equipped for mechanical stirring while providinga nitrogen environment on the reactants. The mixture was then spargedwith nitrogen for about five minutes. A requisite amount ofazo-bis-butyronitrile (Azo) was added to the mixture. In most cases,isopropyl alcohol (IPA) sparged with nitrogen was also added to themixture. The mixture was heated to the desired temperature undernitrogen and stirred for a certain period of time until the commencementof the second step.

In the second step of the synthesis, a second aliquot of the Azo freeradical initiator and IPA were added prior to introduction of a secondcharge of monomer or comonomer. The monomer and comonomer were alsosparged with nitrogen. The polymerization was continued at the desiredtemperature until monomer consumption practically ceased, maintainingagitation while possible.

At the conclusion of the second step, the heating was stopped and theproduct was mixed in the reactor with a suitable solvent such as acetoneto facilitate the polymer purification by precipitation in a coldnon-solvent such as water or methanol or a mixture thereof. Theprecipitated copolymer was then isolated by filtration and allowed todry in a laminar flow hood under reduced pressure at room temperatureuntil a constant dry weight was achieved. Further drying can beaccomplished by heating under reduced pressure until a constant dryweight is achieved.

EXAMPLE 1B General Methods of Analysis

A set of general analysis methods was used to monitor and characterizethe polymerization reactions. In-process monitoring of thepolymerization reaction was achieved by the analysis of residualmonomers and molecular weight build-up using gel permeationchromatography (GPC) with dichloromethane as a solvent.

The purified copolymer was characterized with infrared analysis using afilm prepared from a chloroform solution. The composition of thepurified copolymer was determined with nuclear magnetic resonance (NMR),using CDCL₃ as a solvent. Number average (Mn) and weight average (M_(w))molecular weights were measured using GPC with dichloromethane (DCM) ortetrahydrofuran (THF) as a solvent, and the inherent viscosity (I.V.)with chloroform.

EXAMPLE 1C General Method of Film Formation and Determination of PercentElongation

Fracture strain characteristics of the polymeric material may bemeasured by forming the polymer into a sheet, and applying strain to asample of the material, and determining when the sample breaks, therebydetermining the fracture strain.

The dried polymer was compression-molded into a film about 0.1 mm thickusing a heated laboratory Carver press. The temperature, pressure, andtime used varied with the copolymer composition—typically above 50° C.,3,000 lbs, and 2 minutes, respectively. The pressed polymer was thenquick-quenched to about 25° C. and removed. The molded film was cut into13×40 mm pieces. The percent elongation was determined on a Mini-BionixUniversal Tester using a gauge length of 19 mm and strain rate of 0.5mm/s.

EXAMPLES 2A-2J Two-Step Synthesis of VAc and BMA Segmented ChainCopolymer with BMA in the Second Step

A segmented chain copolymer was synthesized in a two-step procedureusing only BMA in the second step. Reaction charge and conditions forthe preparation of ten copolymers are summarized in Table 3A and Table3B. The copolymers were made using a (1) high VAc to BMA ratio and onlyBMA in the second step; (2) polymerization temperature of 55° C. to 70°C.; and (3) no or variable amounts of IPA.

TABLE 3A TWO-STEP SYNTHESIS AND PROPERTIES OF SEGMENTED VAC TO BMACOPOLYMERS USING ONLY BMA IN THE SECOND STEP Example Number 2A 2B 2C 2D2E Step 1 VAc/BMA (g/g) 8/2 23/6  94/100 90/10 80/20 Azo (mg) 38 100 249249 300 IPA (mL) 0 0 100 10 10 R Time (hour)/Temp  1/70  1/70 20/6023/60 53/55 (° C.) Step 2 BMA/VAc (g/g) 8/0 22/0  100/0  100/0  100/0 Azo (mg) 0 0 101 101 80 IPA (ml) 0 0 100 100 100 R Time (hour)/Temp35/70 35/70 26/60 21/60 37/60 (° C.) Polymer Properties 1.04 1.44 0.61.24 0.75 I.V. M_(w) (kDa)¹  >377² 258 163 395 222 Elongation(%) >250 >250 >250 >250 >250 ¹In DCM or otherwise as indicated. ²In THF.

TABLE 3B TWO-STEP SYNTHESIS AND PROPERTIES OF SEGMENTED VAC AND BMACOPOLYMERS USING ONLY BMA IN THE SECOND STEP Example Number 2F 2G 2H 2I2J Step 1 VAc/BMA (g/g) 25/8  20/8  18/10 70/10 70/10 Azo (mg) 105 100105 250 250 IPA (mL) 0 0 0 10 10 R Time (hour)/Temp  1/70  1/70  1/7054/60 46/60 (° C.) Step 2 BMA/VAc (g/g) 22/0  20/0  22/0  120/0  120/0 Azo (mg) 0 0 0 80 80 IPA (mL) 0 0 0 12 20 R Time (hour)/Temp 35/70 35/7035/70 30/60 23/60 (° C.) Polymer Properties I.V. 1.66 1.39 1.63 0.810.74 M_(w) (kDa)¹ 273 268 275 225 264 Elongation(%) >250 >250 >250 >250 >250 ¹In DCM.

EXAMPLES 3A AND 3B Two-Step Synthesis of Segmented Polymers of EthylMethacrylate with Two Other Comonomers

A segmented copolymer was synthesized in a two-step process using ethylmethacrylate (EMA) and two other comonomers. Reaction charge andconditions for the bulk preparation (no IPA was used) of a segmentedcopolymer of EMA with VAc and BMA are summarized in Table 4 for Example3A. No IPA was used in the preparation. Example 3B is also described inTable 4. It is based on EMA, ethoxyethyl methacrylate (ETOEMA) and BMA.The properties of the polymers in Examples 3A and 3B are also outlinedin Table 4.

TABLE 4 TWO-STEP SYNTHESIS AND PROPERTIES OF SEGMENTED POLYMERS OF ETHYLMETHACRYLATE (EMA) WITH TWO OTHER COMONOMERS Example Number 3A 3B Step 120/15 20/7.5 Added Monomers (g) VAc/EMA ETOEMA/EMA Azo (mg) 100 100 RTime (hour)/Temp (° C.) 2.5/70  0.7/70  Step 2 7.5 22.5 Added Monomer(g) BMA BMA R Time (hour)/Temp (° C.) 34/70  2/70 Polymer PropertiesI.V. 1.84 1.57 M_(w) (kDa)* — — Elongation (%) >250 >250 *In DCM.

EXAMPLES 4A-4E Synthesis of Segmented BMA and VAc Copolymers with atLeast 90:10 BMA to VAc Comonomer Ratio

A segmented BMA-VAc copolymer with a BMA to VAc comonomer ratio of atleast 90:10 was synthesized. A two-step synthetic scheme was used toprepare the copolymer of Example 4A and entailed 1) a brief first stepof one copolymerization cycle associated with incomplete consumption ofthe comonomer; and 2) the addition of a second aliquot of Azo initiatorat the beginning of the second copolymerization step. In Example 4B, thecopolymerization was conducted in an extended single step using a highsingle dose of the Azo initiator. The synthesis of Examples 4C and 4Dpolymers entailed preparing a low molecular prepolymer of one type inthe first step and adding a monomer mixture that was rich in BMA in thesecond step. In Example 4E, a slightly higher temperature was used inthe second step. Reaction charges for the preparation of the copolymersof Examples 4A to 4E and their properties are summarized in Table 5.

TABLE 5 SYNTHESIS AND PROPERTIES OF BMA AND VAC SEGMENTED COPOLYMERSWITH AT LEAST 90:10 BMA:VAC COMONOMER RATIO Example Number 4A 4B 4C 4D4E Step 1 VAc/BMA (g/g) 10.5/200   20/180 15/0   0/195 15/0  Azo (mg)250 300 200 200 200 IPA (mL) 100 100 100 150 100 R Time (hr)/Temp 10/6521/65 16/65 12/65 16/65 (° C.) Step 2 BMA/VAc (g/g) 0/0 0/0  5/18010.5/5    5/180 Azo (mg) 50 50 150 200 150 R Time (hr)/Temp  7/65  7/6512/65 16/65 12/70 (° C.) Polymer Properties I.V. 1.08 — — — — M_(w)(kDa)* 314 183 260 300 310 Elongation (%) >250 >250 >250 >250 >250 *InDCM.

EXAMPLES 5A-5D Synthesis of Segmented VAc and BMA Copolymers with atLeast 90:10 VAc:BMA Comonomer Ratio

A segmented VAc and BMA copolymer with greater than 90:10 VAc to BMAcomonomer ratio was synthesized in a two-step process. The two-stepsynthesis schemes outlined in Table 6 were used to prepare thecopolymers of Examples 5A and 5B. These entailed 1) charging allreactants at the first step; 2) using a relatively higher Azoconcentration than those used in the previous examples; 3) extending thereaction time in the first step; and 4) limiting the reactiontemperature in the second step to 25° C. For the copolymers of Examples5C and 5D as in Table 6, the BMA was charged at both steps and anadditional amount of IPA was used in the second step.

TABLE 6 SYNTHESIS AND PROPERTIES OF VAc AND BMA SEGMENTED COPOLYMERSWITH AT LEAST 90:10 VAC:BMA COMONOMER RATIO Example 5A 5B 5C 5D VAc/BMA(g/g) 190/10  180/20  180/10  180/15  Azo (mg) 300 300 300 300 IPA (mL)100 100 100 100 R time (hour)/Temp (° C.) 30/65 30/65 30/65 30/65 Step 2BMA/VAc (g/g) 0/0 0/0  0/10 0/5 Azo (mg) 0 0 0 0 IPA (mL) 0 0 100 100 Rtime (hour)/Temp (° C.) 12/25 12/25 12/65 12/65 Polymer Properties I.V.— 0.25 — — M_(w) (kDa)* — 59 — — Elongation (%) >250 >250 >250 >250 *InDCM.

EXAMPLE 6 Synthesis of Segmented VAc and BMA Copolymer with 50:50VAc:BMA Comonomer Ratio

A segmented VAc and BMA copolymer with approximately 50:50 VAc:BMAcomonomer ratio by weight was synthesized in a multi-step process. Themulti-step synthetic scheme was used to prepare the 50:50 copolymerfollowing the general experimental protocol as described in Example 1for VAc and BMA copolymerization with the Azo initiator and IPA as adilutent and reaction medium. In the first step, 85 g of VAc was allowedto copolymerize with 10 g of BMA using 200 mg of the Azo initiator and75 mL of IPA. The polymerization was conducted at 65° C. for 24 hours.At the conclusion of the first step, a mixture of 5 g VAc, 30 g BMA, 50mg Azo, and 25 mL IPA was added to the reaction product to proceed withthe second step. At this step, the copolymerization was conducted at atemperature at about 65° C. for 6 hours. A similar charge was used inthe third step, and the copolymerization was conducted at 65° C. for 16hours. In the fourth step, the same comonomer, Azo and IPA charge wasused, and the copolymerization was conducted at 65° C. for 16 hours. Atthe conclusion of the fourth step, the copolymer may be isolated,purified, and characterized in the manner as described in Example 1.

EXAMPLE 7 Synthesis of Segmented Interpenetrating VAc and BMA Copolymerwith an Overall Comonomer Ratio of 50:50

A segmented copolymer consisting of interpenetrating VAc and BMAsequences with an average comonomer ratio of 50:50 by weight wassynthesized. The polymerization was conducted in two steps under thegeneral experimental conditions noted in earlier examples. In the firststep, a mixture of 90 g VAc, 10 g BMA, 350 mg Azo, and 100 mL IPA washeated at 65° C. for 24 hours. At the conclusion of the first step, amixture of 10 g VAc, 90 g MBA and 50 mL IPA was added to the reactionmixture, and heated to 65° C. and held there for 16 hours during thesecond step. The resulting polymer may be isolated, purified, andcharacterized as described in previous examples.

EXAMPLE 8 Synthesis of Segmented Interpenetrating VAc, nHMA and NVPTerpolymer with an Overall Monomer Ratio of 30:40:30

A segmented terpolymer consisting of interpenetrating VAc, nHMA and NVPsequences with an average monomer ratio of approximately 30:40:30 byweight was synthesized as follows. However, it is understood that thefollowing synthetic process can be used to synthesize numerousterpolymers have the same monomer constituents by with different monomerratios merely by differing the relative concentrations of the startingmaterials in accordance with the teachings of the present invention.

Materials

-   -   a) 1-Vinyl-pyrrolidinone, 99+%, Aldrich catalog # V340-9 (UN        08229KA), (vacuum distilled before use).    -   b) Vinyl acetate, 99+%, Aldrich catalog # V150-3 (UN 03625DA)    -   c) n-Hexyl methacrylate, TCI America catalog # M0503 (UN GBO1)    -   d) 1,4-Dioxane, HPLC grade, 99.9%, Aldrich catalog # 27053-9        (L/N 02062DA)    -   e) 2, 2′-Azobisisobutyronitrile (AIBN), Aldrich catalog #        44109-0 (L/N 01313EA)    -   f) Hexanes, ACS reagent grade, 98.5%, Aldrich catalog # 44349-2        (L/N 07346HA)    -   g) Methanol, HPLC grade, Aldrich catalog #270474 (UN 03935LA)

Equipment

-   -   a) 500 mL Reaction kettle (VWR catalog # 36390-020, Clamp VWR        catalog # 36393-030)    -   b) Stirring shaft (Chemglass catalog # CG-2079A-02)    -   c) Stirrer bearing (teflon) (Chemglass catalog # CG-2077-01)    -   d) Thermocouple (Controls Corp.)    -   e) HPLC delivery pump (Rabbit-HP HPX)    -   f) Balance (Meffler PM 4600)    -   g) Ace thread # 7 with N2 inlet (Aceglass catalog # 5261-16)

Formulation of Charges Weight (g) Charge One Vinyl acetate 25 1-Vinylpyrrolidone 6.5 n-Hexyl methacrylate 8.5 1,4-Dioxane 50 AIBN 0.375Charge Two 1-Vinyl pyrrolidone 20.5 Hexyl methacrylate 40 1,4-Dioxane 60AIBN 0.45

Procedures

-   -   1) A 500 mL reaction kettle equipped with a mechanical stirrer        (Teflon bearing and glass stirring shaft), a thermocouple        adapter with N₂ inlet an adapter for Charge Two addition tubing        and a condenser capped with N₂ reaction bubbler, is charged with        Charge One.    -   2) A 20% excess of Charge Two is prepared and stored in a        bottle. The Charge Two bottle is capped with a rubber septum        thread with Teflon tubing, which is connected to a HPLC delivery        pump. The tubing was filled with Charge Two solution. Charge Two        bottle is purged with N₂ for 2 minutes.    -   3) The kettle is purged with N₂ at a flow rate of about a        bubble/sec while under stirring for 20 minutes at room        temperature. The N₂ bubbling is reduced just enough to maintain        a positive pressure.    -   4) The reaction kettle is lowered to a preheated water bath        (temperature set at about 62° C.). The temperature should reach        60° C. in about 5-10 minutes. The reaction is stirred at 60° C.        for 25 minutes before Charge Two is added at a rate of 20.16        g/hour. After 120.95 g of Charge Two is added (6 Hours), stop        the HPLC pump and the reaction.    -   5) The reaction kettle is removed from the water bath and        reaction is exposed to air and cooled to room temperature with        an ice water bath.

The polymer solution is diluted with 2 L of hexanes and the solution istransferred to a flask. The polymer solution in hexanes is cooled to−60° C. with a dry ice-isopropyl alcohol bath for 30 minutes toprecipitate out the polymer. The system is warmed up to −40° C. The topsolution is decanted as much as possible. The sticky polymer isredissolved in 2 L of hexanes. If the polymer does not completelydissolve at room temperature, warm it up with a water bath to raise thetemperature to 50 C. Add just enough chloroform for the polymer todissolve completely. The cold temperature precipitation is repeated twomore times. The polymer is redissolved in 125 mL chloroform andprecipitated in 1500 mL methanol cooled to −60° C. The solvent isdecanted and the polymer is pressed and washed with some cold methanol.This precipitation is repeated one mote time. The sticky polymer isdissolved in 250 mL of chloroform and transferred to Teflon lined trays.After most of the chloroform is evaporated inside a hood, the polymer isdried in a vacuum oven set at 45° C. under a vacuum of <1 mm Hgovernight. The transparent polymer film is peeled off the Teflon tray.

EXAMPLE 9 Synthesis of Segmented 94:5 VAc:BMA Copolymer Grafted withShort 1:20 VAc:BMA Chains, for an Overall Comonomer Ratio of 95:25VAc:BMA

A segmented copolymer consisting of a 94:5 VAc:BMA copolymer graftedwith short 1:20 VAc:BMA chains was synthesized in accordance withanother embodiment of the present invention, to form a grafted copolymerwith an overall comonomer ratio of 95:25. The polymerization wasconducted in two steps, under the usual experimental conditions noted inearlier examples. In the first step, a mixture of 94 g VAc, 5 g BMA, 250mg Azo, and 100 mL IPA was heated at 65° C. for 24 hours. At theconclusion of this period, 100 mL of IPA were added to the reactionproduct. This was followed by adding 50 mg of Azo and continuing theheating at 65° C. for 5 minutes prior to adding a mixture of 1 g VAc and20 g BMA, and then proceeding with the second step of thecopolymerization at 65° C. for 12 hours. The resulting polymer may beisolated, purified, and characterized as described in previous examples.

EXAMPLE 10 Preparation of Poly(n-Butyl Methacrylate)

In another embodiment of the current invention, a segmented copolymerwas prepared with poly(n-butyl methacrylate). This entailed the use of200 g BMA, 408 mg Azo initiator, and 150 mL IPA. The polymerization wasconducted at 65° C. for 18 hours. The resulting polymer was isolated,purified, and characterized in the usual manner (see Example 1). Thepolymer was shown to have an I.V. of 0.82 dL/g, M_(w) (DCM) of 263kiloDalton (kDa), and its film did not break at over 300% elongation.

Solubility Parameter (δ and δ_(T)) Determinations

The solubility parameters of the polymers, compatibilized polymer blendsand the bioactive agents used in the present invention were calculatedusing methods known to those having ordinary skill in the art. Forexample, see van Krevelen at pages 189 through 226. Specifically seepages 211 through 219. Generally, and not intended as a limitation,there are two accepted methods for calculating solubility: theHoftyzer-van Kreveln method and the Hoy method. (See for examples:Hoftyzer, P. J. and van Krevelen, D. W. 1976 Properties of Polymers, 2dEdition, Chapter 7, pp 152-155) and Hoy (Hoy, K. L. 1970. J. PaintTechn. 42:76; Tables of Solubility Parameters. Solvent and Coatings.Materials Research and Development Department, Union CarbideCorporation. 1985. and J. Coated Fabrics 1989. 19:53). The resultsobtained using the algorithmic methods of Hoftyzer-van Krevelen and Hoyare usually within 10% of each other. Therefore, in many casescalculating the solubility parameters for a polymer or other organiccompound using both methods and then averaging the results is preferred.However, experimental methods of determining polymer solubility may beused as well.

PREPARATION OF COMPATIBLE CONTROLLED RELEASE COATINGS I. Preparation ofStock Solutions

Stock solutions were prepared containing 1% (wt/wt %) of polymercomposition or drug dissolved in chloroform according to Table 7.

TABLE 7 PREPARATION OF STOCK SOLUTIONS Polymer or Drug Weight of Volumeof Chloroform Composition Polymer or Drug (sp gr 1.492) PEVAc 0.4659 g30.9 mL Polymer A 0.1421 g  9.4 mL Polymer B 0.4233 g 28.1 mL Polymer C0.4432 29.4 mL Drug rapamycin 0.2936 g 19.5 mL Drug evrolimus 0.0925 g 6.1 mL

II. Preparation of Compatibilized Coating Solutions

Five mL volumes of compatibilized coating solutions were prepared byblending predetermined amounts of stock solutions defined in Table 8 inaccordance to the following ratios.

TABLE 8 PREPARATION OF COMPATIBILIZED COATING COMPOSITIONS CoatingVolume of Volume and Polymer- ID Volume of Drug PEVc CopolymerComposition I evrolimus 1.25 mL 1.875 mL Copolymer A 1.875 mL IIevrolimus 1.25 mL  1.5 mL Copolymer A 2.25 mL III rapamycin 1.25 ml1.875 ml   Copolymer B 1.875 mL IV rapamycin 1.25 mL  1.5 mL Copolymer B2.25 mL V rapamycin 1.25 ml  1.5 mL Copolymer B 1.875 mL Copolymer C0.375 mL VI rapamycin 1.25 mL  1.5 mL Copolymer B 1.5 mL Copolymer C0.75 mL VII rapamycin 1.25 mL 1.875 mL Copolymer B 1.56 mL Copolymer C0.31 mL VIII rapamycin 1.25 mL 1.875 mL Copolymer B 1.25 mL Copolymer C0.625 mL IX rapamycin 1.25 mL  2.25 mL Copolymer B 1.25 mL Copolymer C0.25 mL X rapamycin 1.25 ml  2.25 mL Copolymer B 1.00 mL Copolymer C0.50 mL

EXAMPLE 11 Preparation of an ABT-578-Matrix™ Coating for an ImplantableMedical Device

Preparation of the Stock Solutions:

Weigh 1.6590 g of ABT578 in a clean glass bottle and add 110.1 ml ofchloroform. Mix to dissolve the ABT 578.

Weigh 1.1278 g of C10 in a clean glass bottle and add 74.8 ml ofchloroform. Mix to dissolve the polymer.

Weigh 1.0555 g of C19 in a clean glass bottle and add 70 ml ofchloroform. Mix to dissolve the polymer.

Weigh 1.2341 g of polyvinyl pyrrolidone (PVP) K30 (e.g. Povidone 30 USPK value 26-35 [approximately] molecular weight 15 to 22 kDa by GPC[approximately]) in a clean glass bottle and add 81.9 ml of chloroforminto the same bottle. Mix to dissolve the polymer.

TABLE 9 PREPARATION OF MATRIX ™ COATING COMPONENT COMPOSITIONS ComponentABT578 C10 C19 PVP Wt (g) 1.6590 1.1278 1.0555 1.2341 Chloroform (ml)110.1 74.8 70 81.9

TABLE 10 Matrix ™ Coating Component Solubility Parameters Componentδ_(T) C10 17.6 C19 19.6 PVP 30.1 Matrix ™ 20.1 ABT-578 23.7

Preparation of Coating Solution

Pipette 35 ml of the ABT-578/chloroform solution and transfer it into aclean glass bottle.

Pipette 17.55 ml of the C10/chloroform solution and transfer it into thesame glass bottle.

Pipette 40.95 ml of the C19/chloroform solution and transfer it into thesame glass bottle.

Pipette 6.5 ml of the PVP/chloroform solution and transfer it into thesame glass bottle.

Mix the bottle until uniform solution is formed. Filter the resultingsolution through a 0.25μ PTFE filter into a clean bottle.

TABLE 11 Preparation of Matrix ™ Coating Composition Solution ABT578 C10C19 PVP (ml) 35 17.55 40.95 6.5

APPLICATION PROCESS

As previously discussed, the compatibilized coating solutions of thepresent invention can be applied to virtually any medical device surfaceusing standard coating techniques including spraying, dipping, orpainting. In one embodiment of the present invention the compatibilizedcoatings are sprayed onto the surface of a vascular stent that has beenpreviously provided with a parylene C primer coat. The parylene C havingbeen applied first to the cleaned, bare stent surface using vacuumdeposition.

Spraying was carried out in an isolator employing an ultrasonic spraydevice. The spray device's coating chamber was filled with thecompatibilized coating solution of the present invention and programmedto deliver approximately 45 μg per mm of stent. In one embodiment 400 μgof compatibilized coating was loaded on a 9 mm stent. The stents weremounted onto a mandrel and sprayed. After the spraying operation wascomplete the stent was dried under vacuum at room temperature overnight.

In one embodiment of the present invention a parylene primed stent wasprovided with a coating comprising the terpolymer composition D in Table1 containing a bioactive agent and a non-drug containing second barriercoat comprising co-polymer composition B in Table 1.

TESTING Coating Durability

The compatibilized control release coatings of the present inventionwere tested for durability using a tortuous path tubing system as shownin FIG. 3. Coated stents were mounted on balloon catheters and insertedinto the tubing system. The catheter was inserted and removed threetimes to simulate the wear a stent might endure during insertion andmanipulation. Finally the catheter was inflated in a physiological-likeenvironment and the stent coating was examined using high resolutionoptics and scanning electron microscopy for signs of delamination,cracking and excessive wear.

DRUG ELUTION PROFILES

The coated stents were placed in two milliliters of 10 mmole TRIS (pH6.5) containing 4% sodium dodecyl sulfate (SDS) (TRIS-SDS buffer) andincubated at 37° C. for a total of 28 days. Samples were taken at every24 hours up to 7 days. After the initial 24 hour incubation the stentswere placed in fresh TRIS-SDS buffer and incubated for an additional 24hours at which point they were samples again and then placed in freshTRIS-SDS buffer. After 7 days, the samples were taken every 48 hours,this process was repeated for 28 consecutive days. Samples. Test sampleswere analyzed for drug concentration using HPLC.

FIG. 7 graphically depicts the elution profile for Matrix™ when blendedwith ABT-578. Note that the elution of ABT-578 was tested under fourconditions. Diamonds depict the ABT-578 elution kinetics when C10 is theonly controlled release polymer used. Triangles depict the ABT-578elution kinetics when a C10/C19 blend is the only controlled releasepolymer used. Squares depict the ABT-578 elution kinetics when C19 isthe only controlled release polymer used. Finally, “x” depicts theABT-578 elution kinetics when Matrix™ is the controlled release polymerused. It is interesting to note, that consistent with the teachings ofthe present invention, the closer the δ_(T) of the polymer is to thedrug's δ_(T) the greater the amount of drug release over time. Forexample, the δ_(T) of ABT-578 is approximately 23.7 and the δ_(T) forMatrix™ is 20.1 (the δ_(T) for the drug being at least 15% greater thanthe δ_(T) for the component of the coating). This combination gives thegreatest amount of drug released over time. Matrix™ has the highestδ_(T) among all of the polymers tested in this experiment. The secondhighest releasing polymer is coating is C19 (the δ_(T) for the drugbeing between 20% to 15% greater δ_(T) for the polymer component of thecoating) which has the second highest δ_(T) whereas C10 (the δ_(T) forthe drug being at 20% greater than the δ_(T) for component of thecoating), which has the lowest δ_(T) exhibits to least amount of ABT-578released over time. These experiment data support the non-limitingtheory of the present invention that drug eluting coatings for medicaldevices can be designed to achieve precise drug elution kinetics usingthe relative δ_(T) of the coating polymers and drug.

CONCLUSION

Drug eluting polymer coatings for medical devices are becomingincreasingly more common. Furthermore, the number of possiblepolymer-drug combinations is increasing exponentially. Therefore, thereis need for reproducible methods of designing drug-polymer compositionssuch that drug-elution rates/profiles, biocompatibility and structuralintegrity are compatibilized resulting in optimal coating systemstailored for specific therapeutic functions. The present inventionprovides both exemplary optimal coating systems and related methods fortheir reproducible design.

Unless otherwise indicated, all numbers expressing quantities ofingredients, properties such as molecular weight, reaction conditions,and so forth used in the specification and claims are to be understoodas being modified in all instances by the term “approximately.”Accordingly, unless indicated to the contrary, the numerical parametersset forth in the following specification and attached claims areapproximations that may vary depending upon the desired propertiessought by the present invention. At the very least, and not as anattempt to limit the application of the doctrine of equivalents to thescope of the claims, each numerical parameter should at least beconstrued in light of the number of reported significant digits and byapplying ordinary rounding techniques. Notwithstanding that thenumerical ranges and parameters setting forth the broad scope of theinvention are approximations, the numerical values set forth in thespecific examples are reported as precisely as possible. Any numericalvalue, however, inherently contains certain errors necessarily resultingfrom the standard deviation found in their respective testingmeasurements.

The terms “a” and “an” and “the” and similar referents used in thecontext of describing the invention (especially in the context of thefollowing claims) are to be construed to cover both the singular and theplural, unless otherwise indicated herein or clearly contradicted bycontext. Recitation of ranges of values herein is merely intended toserve as a shorthand method of referring individually to each separatevalue falling within the range. Unless otherwise indicated herein, eachindividual value is incorporated into the specification as if it wereindividually recited herein. All methods described herein can beperformed in any suitable order unless otherwise indicated herein orotherwise clearly contradicted by context. The use of any and allexamples, or exemplary language (e.g., “such as”) provided herein isintended merely to better illustrate the invention and does not pose alimitation on the scope of the invention otherwise claimed. No languagein the specification should be construed as indicating any non-claimedelement essential to the practice of the invention.

Groupings of alternative elements or embodiments of the inventiondisclosed herein are not to be construed as limitations. Each groupmember may be referred to and claimed individually or in any combinationwith other members of the group or other elements found herein. It isanticipated that one or more members of a group may be included in, ordeleted from, a group for reasons of convenience and/or patentability.When any such inclusion or deletion occurs, the specification is hereindeemed to contain the group as modified thus fulfilling the writtendescription of all Markush groups used in the appended claims.

Preferred embodiments of this invention are described herein, includingthe best mode known to the inventors for carrying out the invention. Ofcourse, variations on those preferred embodiments will become apparentto those of ordinary skill in the art upon reading the foregoingdescription. The inventor expects skilled artisans to employ suchvariations as appropriate, and the inventors intend for the invention tobe practiced otherwise than specifically described herein. Accordingly,this invention includes all modifications and equivalents of the subjectmatter recited in the claims appended hereto as permitted by applicablelaw. Moreover, any combination of the above-described elements in allpossible variations thereof is encompassed by the invention unlessotherwise indicated herein or otherwise clearly contradicted by context.

Furthermore, numerous references have been made to patents and printedpublications throughout this specification. Each of the above citedreferences and printed publications are herein individually incorporatedby reference in their entirety.

In closing, it is to be understood that the embodiments of the inventiondisclosed herein are illustrative of the principles of the presentinvention. Other modifications that may be employed are within the scopeof the invention. Thus, by way of example, but not of limitation,alternative configurations of the present invention may be utilized inaccordance with the teachings herein. Accordingly, the present inventionis not limited to that precisely as shown and described.

1. A medical device comprising a controlled release coating comprising:a polymer component comprising a terpolymer-co-polymer-homopolymerpolymer blend and a drug, wherein the δ_(T) for the drug is within ±10J^(1/2)/cm^(3/2) of the total solubility parameter δ_(T), for thepolymer component; and wherein said terpolymer comprises monomersubunits consisting essentially of vinyl acetate (VAc), alkylmethacrylate (AMA) and n-vinyl pyrrolidone (NVP), said co-polymercomprises monomer subunits consisting essentially of VAc and AMA, andsaid homopolymer is polyvinyl pyrrolidone, wherein: the terpolymer has aTg of 15° C. to 20° C.; the co-polymer has a Tg of 32° C. to 35° C.; thehomopolymer has a Tg of 174° C.; and the polymer blend comprises 20-30%co-polymer, 60-70% terpolymer, and 5-15% homopolymer.
 2. The medicaldevice according to claim 1 wherein said relative mole percentconcentrations of said monomer subunits in said terpolymer comprises5-30% (VAc), 40-77% (AMA) and 18-30% (NVP).
 3. The medical deviceaccording to claim 1 wherein said relative mole percent concentrationsof said monomer subunits in said co-polymer comprises 5-70% VAc and30-95% AMA.
 4. The medical device according to claim 1 wherein saidalkyl methacrylate is selected from the group consisting of methylmethacrylate, ethyl methacrylate, propyl methacrylate, butylmethacrylate, pentyl methacrylate, and hexyl methacrylate.
 5. Themedical device according to any one of claim 1 through 4 wherein saidδ_(T) for the polymer component is approximately 15 to
 21. 6. Themedical device according to claim 1 wherein said drug is rapamycin,everolimus or ABT-578.
 7. The medical device of claim 1 wherein thecoating is biocompatible, non-thrombogenic, non-inflammatory,lubricious, and non-bioerodable.
 8. A medical device comprising acontrolled release coating comprising: a polymer component comprising aterpolymer-co-polymer-homopolymer polymer blend, wherein: the terpolymerand co-polymer each include vinyl acetate; the terpolymer has a low Tgrelative to the Tg of the co-polymer and homopolymer; the co-polymer hasan intermediate Tg relative to the Tg of the terpolymer and homopolymer;the homopolymer has a high Tg relative to the Tg of the co-polymer andterpolymer; wherein the terpolymer has a Tg of 15° C. to 25° C.; and thepolymer blend comprises 20-30% co-polymer, 60-70% terpolymer, and 5-15%homopolymer; and a drug, wherein the δ_(T) for the drug is within ±10J^(1/2)/cm^(3/2) of the total solubility parameter δ_(T) for the polymercomponent.
 9. The medical device of claim 8 wherein the co-polymer has aTg of 30° C. to 40° C.
 10. The medical device of claim 8 wherein thehomopolymer has a Tg of 170° C. to 180° C.
 11. The medical deviceaccording to claim 8 wherein said coating has a glass transition point(Tg) from approximately −20° C. to 50° C.
 12. The medical deviceaccording to claim 8 wherein said terpolymer comprises monomer subunitsconsisting essentially of vinyl acetate (VAc), alkyl methacrylate (AMA)and n-vinyl pyrrolidone (NVP), said co-polymer comprises monomersubunits consisting essentially of VAc and AMA, and said homopolymer ispolyvinyl pyrrolidone.
 13. The medical device according to claim 12wherein said relative mole percent concentrations of said monomersubunits in said terpolymer comprises 5-30% (VAc), 40-77% (AMA) and18-30% (NVP).
 14. The medical device according to claim 12 wherein saidrelative mole percent concentrations of said monomer subunits in saidco-polymer comprises 5-70% VAc and 30-95% AMA.
 15. The medical deviceaccording to claim 12 wherein said alkyl methacrylate is selected fromthe group consisting of methyl methacrylate, ethyl methacrylate, propylmethacrylate, butyl methacrylate, pentyl methacrylate, and hexylmethacrylate.
 16. The medical device according to any one of claim 11through 15 and claim 8 wherein said δ_(T), for the polymer component isapproximately 15 to
 21. 17. The medical device according to claim 8wherein said drug is selected from the group consisting of macrolideantibiotics, FKBP 12 binding compounds, estrogens, chaperone inhibitors,protease inhibitors, protein-tyrosine kinase inhibitors, peroxisomeproliferator-activated receptor gamma ligands (PPARγ), hypothemycin,nitric oxide, bisphosphonates, epidermal growth factor inhibitors,antibodies, antibiotics, proteasome inhibitors anti-sense nucleotidesand transforming nucleic acids.
 18. The medical device according toclaim 17 wherein said antibiotic is a FKBP 12 binding compound.
 19. Themedical device according to claim 18 wherein said FKBP 12 bindingcompound is a macrolide antibiotic.
 20. The medical device according toclaim 19 wherein said macrolide antibiotic is rapamycin, everolimus orABT-578.
 21. The medical device of claim 8 wherein the coating isbiocompatible, non-thrombogenic, non-inflammatory, lubricious, andnon-bioerodable.
 22. A vascular stent comprising a structure: saidstructure comprising a material having a hydrophobic polymer disposedthereon; a controlled release coating over said hydrophobic polymerwherein said controlled release coating comprises a polymer componentcomprising a terpolymer-co-polymer-homopolymer polymer blend, wherein:the terpolymer and co-polymer each include vinyl acetate; the terpolymerhas a low Tg relative to the Tg of the co-polymer and homopolymer; theco-polymer has an intermediate Tg relative to the Tg of the terpolymerand homopolymer; the homopolymer has a high Tg relative to the Tg of theco-polymer and terpolymer; wherein the terpolymer has a Tg of 15° C. to25° C.; and the polymer blend comprises 20-30% co-polymer, 60-70%terpolymer, and 5-15% homopolymer; and a bioactive agent, wherein theδ_(T) for the bioactive agent is within ±10 J^(1/2)/cm^(3/2) of thetotal solubility parameter δ_(T) for the polymer component.
 23. Thevascular stent of claim 22 wherein the co-polymer has a Tg of 30° C. to40° C.
 24. The vascular stent of claim 22 wherein the homopolymer has aTg of 170° C. to 180° C.
 25. The vascular stent according to claim 22wherein said hydrophobic polymer is parylene.
 26. The vascular stentaccording to claim 22 wherein said terpolymer comprises monomer subunitsconsisting essentially of vinyl acetate (VAc), alkyl methacrylate (AMA)and n-vinyl pyrrolidone (NVP), said co-polymer comprises monomersubunits consisting essentially of VAc and AMA, and said homopolymer ispolyvinyl pyrrolidone.
 27. The vascular stent according to claim 26wherein said relative mole percent concentrations of said monomersubunits in said terpolymer comprises 5-30% (VAc), 40-77% (AMA) and18-30% (NVP).
 28. The vascular stent according to claim 26 wherein saidrelative mole percent concentrations of said monomer subunits in saidco-polymer comprises 5-70% VAc and 30-95% AMA.
 29. The vascular stentaccording to claim 26 wherein said alkyl methacrylate is selected fromthe group consisting of methyl methacrylate, ethyl methacrylate, propylmethacrylate, butyl methacrylate, pentyl methacrylate, and hexylmethacrylate.
 30. The vascular stent according to any one of claim 25though 29 and claim 22 wherein said δ_(T) for the polymer component isapproximately 15 to
 21. 31. The vascular stent according to claim 22wherein said bioactive agent is selected from the group consisting ofanti-proliferatives including, but not limited to, macrolideantibiotics, FKBP 12 binding compounds, estrogens, chaperone inhibitors,protease inhibitors, protein-tyrosine kinase inhibitors, peroxisomeproliferator-activated receptor gamma ligands (PPARγ), hypothemycin,nitric oxide, bisphosphonates, epidermal growth factor inhibitors,antibodies, antibiotics, proteasome inhibitors anti-sense nucleotidesand transforming nucleic acids.
 32. The vascular stent according toclaim 31 wherein said antibiotic is a FKBP 12 binding compound.
 33. Thevascular stent according to claim 32 wherein said FKBP 12 bindingcompound is a macrolide antibiotic.
 34. The vascular stent according toclaim 33 wherein said macrolide antibiotic is rapamycin, everolimus orABT-578.
 35. The vascular stent of claim 22 wherein the coating isbiocompatible, non-thrombogenic, non-inflammatory, lubricious, andnon-bioerodable.
 36. A vascular stent comprising a structure: saidstructure comprising a material having a hydrophobic polymer disposedthereon; a controlled release coating over said hydrophobic polymerwherein said controlled release coating comprises a polymer componentcomprising a terpolymer-co-polymer-homopolymer polymer blend, wherein:the terpolymer and co-polymer each include vinyl acetate; wherein theterpolymer has a Tg of 15° C. to 20° C., the co-polymer has a Tg of 32°C. to 35° C., and the homopolymer has a Tg of 174° C.; and the polymerblend comprises 20-30% co-polymer, 60-70% terpolymer, and 5-15%homopolymer; and a bioactive agent, wherein the δ_(T) for the bioactiveagent is within ±10 J^(1/2)/cm^(3/2) of the total solubility parameterδ_(T) for the polymer component.
 37. A vascular stent comprising astructure: said structure comprising a material having a controlledrelease coating disposed thereon, said controlled release coatingconsisting essentially of ABT-578 dispersed in a polymer blend, saidpolymer blend consisting essentially of a terpolymer, a co-polymer and ahomopolymer, wherein: said terpolymer comprises approximately 5 mole-%of vinyl acetate, approximately 77 mole-% of n-hexyl methacrylate, andapproximately 18 mole-% of n-vinyl pyrrolidone, said co-polymerconsisting essentially of approximately 5 mole-% of vinyl acetate andapproximately 95 mole-% of n-butyl methacrylate, and said homopolymerconsisting essentially of polyvinyl pyrrolidone, and the polymer blendcomprises 20-30% co-polymer, 60-70% terpolymer, and 5-15% homopolymer,and wherein said controlled release coating comprises approximately 35%by weight ABT-578 and approximately 65% by weight of said polymer blend.38. The vascular stent according to claim 37 wherein said structure iscomposed of a material selected from the group consisting of metals,polymers and biodegradable polymers.